Regen BioPharma Inc RGBPP Financial Statement Data


2025 Q2

Submissions

Field Row 1 Row 2 Row 3
adsh 0001641172-25-012619 0001641172-25-011206 0001641172-25-009968
cik 1589150 1589150 1589150
name REGEN BIOPHARMA INC REGEN BIOPHARMA INC REGEN BIOPHARMA INC
sic 2834 2834 2834
countryba US US US
stprba CA CA CA
cityba LA MESA LA MESA LA MESA
zipba 91942 91942 91942
bas1 4700 SPRING ST #304 4700 SPRING ST #304 4700 SPRING ST #304
bas2
baph 619-722-5505 619-722-5505 619-722-5505
countryma US US US
stprma CA CA CA
cityma LA MESA LA MESA LA MESA
zipma 91942 91942 91942
mas1 4700 SPRING ST #304 4700 SPRING ST #304 4700 SPRING ST #304
mas2
countryinc US US US
stprinc NV NV NV
ein 455192997 455192997 455192997
former
changed
afs 4-NON 4-NON 4-NON
wksi 0 0 0
fye 0930 0930 0930
form 10-Q 10-Q 10-K
period 20250331 20241231 20240930
fy 2025 2025 2024
fp Q2 Q1 FY
filed 20250528 20250516 20250513
accepted 2025-05-28 09:12:00.0 2025-05-16 13:49:00.0 2025-05-13 16:31:00.0
prevrpt 0 0 0
detail 1 1 1
instance form10-q_htm.xml form10-q_htm.xml form10-k_htm.xml
nciks 1 1 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0001641172-25-009968 20240930 Accounts Payable Current 30563.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-012619 20250331 Additional Paid In Capital 15455134.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Accounts Payable Current USD 0 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20230930 Assets 353617.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Assets 161084.0000 USD 0 us-gaap/2024
0001641172-25-009968 20230930 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001641172-25-009968 20230930 Convertible Note Payable Current 10000.0000 USD 0 0001641172-25-009968 Related Party Transactions By Related Party= Related Party;
0001641172-25-009968 20230930 Deferred Revenue Current 15126.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-009968 20240930 Deferred Revenue Current 1465171.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-009968 20240930 Derivative Liabilities 401168.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender Five;
0001641172-25-009968 20230930 Earnings Per Share Basic 0.2900 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Financing Fees 250000.0000 USD 4 0001641172-25-009968
0001641172-25-009968 20230930 Gains Losses On Extinguishment Of Debt 1150.0000 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 1156507.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Increase Decrease In Accounts Payable -7.0000 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Increase Decrease In Accrued Liabilities 58583.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Increase Decrease In Unearned Premiums -141687.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Interest Expense Nonoperating 72445.0000 USD 4 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Liabilities 5378455.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Liabilities Current 5378455.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Liabilities Current 5371640.0000 USD 0 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20230930 Marketable Securities Current 222580.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-009968 20240930 Marketable Securities Current 17733.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-009968 20230930 Net Cash Provided By Used In Operating Activities -173917.0000 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Net Income Loss USD 4 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Net Income Loss USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009968 20230930 Net Income Loss USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009968 20240930 Net Income Loss USD 4 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Net Income Loss USD 4 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Notes Payable Current 100000.0000 USD 0 us-gaap/2024 Debt Instrument= March Eight Two Thousand Sixteen;
0001641172-25-009968 20240930 Operating Income Loss 966.0000 USD 4 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax -204847.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Other Liabilities Current USD 0 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20230930 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-009968 20230930 Preferred Stock Shares Authorized 800000000.0000 shares 0 us-gaap/2024
0001641172-25-009968 20230930 Preferred Stock Shares Issued 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-009968 20240930 Preferred Stock Shares Issued 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-009968 20240930 Preferred Stock Value 3.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Restatement= Restatement;
0001641172-25-009968 20240930 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Restatement= Restatement Adjustment;
0001641172-25-009968 20230930 Retained Earnings Accumulated Deficit -19748863.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Revenue From Contract With Customer Excluding Assessed Tax 236560.0000 USD 4 us-gaap/2024
0001641172-25-009968 20220930 Shares Outstanding 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20220930 Shares Outstanding 7.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Shares Outstanding 10123771.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20220930 Stockholders Equity 12868944.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009968 20240930 Stockholders Equity 3.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Shares New Issues 500000.0000 shares 3 us-gaap/2024 Equity Components= Common Stock; Legal Entity= Coventry Enterprises L L C; Type Of Arrangement= Purchase Agreement;
0001641172-25-009968 20241031 Stock Issued During Period Shares New Issues 15426385.0000 shares 0 us-gaap/2024 Subsequent Event Type= Subsequent Event;
0001641172-25-009968 20230930 Stock Issued During Period Value Common Shares Issued For Financing Expenses 249987.0000 USD 4 0001641172-25-009968 Equity Components= Additional Paid In Capital;
0001641172-25-009968 20240930 Stock Issued During Period Value Common Shares Issued For Financing Expenses USD 4 0001641172-25-009968 Equity Components= Retained Earnings;
0001641172-25-009968 20230930 Stock Issued During Period Value Issued For Services USD 4 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Issued For Services USD 4 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Issued For Services One 48372.0000 USD 4 0001641172-25-009968
0001641172-25-009968 20230930 Stock Issued During Period Value Issued For Services One USD 4 0001641172-25-009968 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Issued For Services One USD 4 0001641172-25-009968 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Other 25369.0000 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Stock Issued During Period Value P Preferred Shares Issued For Interest USD 4 0001641172-25-009968 Equity Components= Retained Earnings;
0001641172-25-009968 20240930 Stock Issued During Period Value Preferred Shares Issued For Dividend USD 4 0001641172-25-009968 Class Of Stock= Preferred Stock Series N C; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Preferred Shares Issued For Dividend USD 4 0001641172-25-009968 Equity Components= Retained Earnings;
0001641172-25-009968 20240930 Stock Issued During Period Value Preferred Shares Issued For Services 13042.0000 USD 4 0001641172-25-009968 Equity Components= Additional Paid In Capital;
0001641172-25-009968 20230930 Stock Issued During Period Value Reverse Stock Splits USD 4 0001641172-25-009968
0001641172-25-011206 20240930 Accounts Payable Current 29669.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Accounts Receivable Net Current 122298.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-011206 20241231 Additional Paid In Capital 15455134.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Assets 191416.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Derivative Liabilities 398293.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender Five;
0001641172-25-011206 20241231 Earnings Per Share Basic -0.1300 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Income Tax Expense Benefit USD 1 us-gaap/2024
0001641172-25-011206 20240930 Liabilities And Stockholders Equity 161084.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Long Term Notes Payable USD 0 us-gaap/2024
0001641172-25-011206 20241231 Marketable Securities Current 17733.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-011206 20241231 Net Income Loss -515385.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-011206 20241231 Net Income Loss Available To Common Stockholders Basic -515384.0000 USD 1 us-gaap/2024
0001641172-25-011206 20240930 Notes Payable Current 293819.0000 USD 0 us-gaap/2024
0001641172-25-011206 20240930 Notes Payable Current 50000.0000 USD 0 us-gaap/2024 Debt Instrument= October Thirty One Two Thousand Sixteen;
0001641172-25-011206 20241231 Notes Payable Current 107507.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Notes Payable Current 59200.0000 USD 0 us-gaap/2024 Debt Instrument= Zander Therapeutics Inc; Related Party Transaction= Related Party;
0001641172-25-011206 20231231 Operating Expenses 181847.0000 USD 1 us-gaap/2024
0001641172-25-011206 20240930 Other Assets 17733.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Other Assets 17733.0000 USD 0 us-gaap/2024
0001641172-25-011206 20240930 Preferred Stock Shares Authorized 60000000.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-011206 20240930 Preferred Stock Shares Issued 34.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Shares Issued 34.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-011206 20240930 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0001641172-25-011206 20240930 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-011206 20240930 Preferred Stock Value 1011.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Value 3.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-011206 20241231 Proceeds From Notes Payable USD 1 us-gaap/2024
0001641172-25-011206 20241231 Professional Fees 84626.0000 USD 1 us-gaap/2024
0001641172-25-011206 20230930 Shares Outstanding 34.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20240930 Shares Outstanding 34.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20230930 Stockholders Equity USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-011206 20230930 Stockholders Equity 14644467.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-011206 20231231 Stockholders Equity 14856739.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-011206 20241231 Stockholders Equity -204847.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-011206 20231231 Stock Issued During Period Shares New Issues 244199.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-011206 20231231 Stock Issued During Period Value New Issues 212296.0000 USD 1 us-gaap/2024
0001641172-25-009968 20230930 Accounts Payable Current 29673.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Accounts Payable Current 29669.0000 USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20240930 Accounts Receivable Net Current 94873.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party; Restatement= Restatement;
0001641172-25-009968 20240930 Accrued Liabilities Current 1664827.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Additional Paid In Capital 15403050.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Assets 177611.0000 USD 0 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Assets Current -16527.0000 USD 0 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Cash And Cash Equivalents At Carrying Value USD 0 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Common Stock Shares Issued 5258235.0000 shares 0 us-gaap/2024
0001641172-25-009968 20220930 Common Stock Shares Outstanding 3354866.0000 shares 0 us-gaap/2024
0001641172-25-009968 20230930 Common Stock Shares Outstanding 3506366.0000 shares 0 us-gaap/2024
0001641172-25-009968 20230930 Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest 1156507.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Convertible Note Payable Current 499880.0000 USD 0 0001641172-25-009968 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-009968 20240930 Derivative Gain Loss On Derivative Net -6817.0000 USD 4 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Derivative Liabilities 1404090.0000 USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20240930 Financing Fees 145500.0000 USD 4 0001641172-25-009968 Restatement= Scenario Previously Reported;
0001641172-25-009968 20230930 Increase Decrease In Accounts Payable 876.0000 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Increase Decrease In Unearned Premiums -111433.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Liabilities 5378456.0000 USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20240930 Liabilities 6816.0000 USD 0 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20230930 Long Term Notes Payable 149614.0000 USD 0 us-gaap/2024
0001641172-25-009968 20230930 Marketable Securities Current USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Related Party Transactions By Related Party= Related Party;
0001641172-25-009968 20240930 Marketable Securities Current 6495.0000 USD 0 us-gaap/2024 Equity Components= Common Stock; Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-009968 20230930 Net Cash Provided By Used In Financing Activities 243750.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Net Cash Provided By Used In Financing Activities 631215.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Net Cash Provided By Used In Operating Activities -751536.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Net Income Loss -668255.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009968 20230930 Notes Payable Current 95710.0000 USD 0 us-gaap/2024
0001641172-25-009968 20230930 Notes Payable Current USD 0 us-gaap/2024 Debt Instrument= Zander Therapeutics Inc; Related Party Transaction= Related Party;
0001641172-25-009968 20240930 Notes Payable Current 293819.0000 USD 0 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Other Liabilities Current 21000.0000 USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20220930 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001641172-25-009968 20220930 Preferred Stock Shares Authorized 600000.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-009968 20220930 Preferred Stock Shares Authorized 60000000.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-009968 20240930 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0001641172-25-009968 20240930 Preferred Stock Shares Issued 15007.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-009968 20220930 Preferred Stock Shares Outstanding 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-009968 20220930 Preferred Stock Shares Outstanding 7.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-009968 20240930 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Preferred Stock; Restatement= Restatement;
0001641172-25-009968 20240930 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Preferred Stock Value 2.0000 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-009968 20230930 Proceeds From Issuance Of Common Stock USD 4 us-gaap/2024
0001641172-25-009968 20240930 Rental Expense 77215.0000 USD 4 0001641172-25-009968
0001641172-25-009968 20230930 Revenue From Contract With Customer Excluding Assessed Tax 236560.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Revenue From Contract With Customer Excluding Assessed Tax USD 4 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20230930 Shares Outstanding 3506366.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009968 20240930 Stockholders Equity -5217372.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Stockholders Equity -20417118.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009968 20240930 Stock Issued During Period Shares Issued For Services 249915.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009968 20240930 Stock Issued During Period Shares Issued Preferred Shares For Services 20068.0000 shares 4 0001641172-25-009968 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Common Shares Issued For Financing Expenses USD 4 0001641172-25-009968 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Issued For Services USD 4 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Issued For Services USD 4 us-gaap/2024 Class Of Stock= Preferred Stock Series N C; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Other 1.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value P Preferred Shares Issued For Interest 380262.0000 USD 4 0001641172-25-009968
0001641172-25-009968 20230930 Stock Issued During Period Value P Preferred Shares Issued For Interest 4.0000 USD 4 0001641172-25-009968 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Preferred Shares Issued For Debt USD 4 0001641172-25-009968 Equity Components= Common Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Preferred Shares Issued For Dividend 969.0000 USD 4 0001641172-25-009968 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Preferred Shares Issued For Dividend USD 4 0001641172-25-009968 Equity Components= Common Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Preferred Shares Issued For Services USD 4 0001641172-25-009968 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Weighted Average Number Of Shares Outstanding Basic 4110265.0000 shares 4 us-gaap/2024
0001641172-25-012619 20240331 Cash Paid For Interest USD 2 0001641172-25-012619
0001641172-25-012619 20250331 Common Shares Issued For Interest USD 2 0001641172-25-012619
0001641172-25-012619 20240930 Common Stock Shares Issued 5258235.0000 shares 0 us-gaap/2024
0001641172-25-012619 20240930 Convertible Note Payable Current 499880.0000 USD 0 0001641172-25-012619 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-012619 20240930 Deferred Revenue Current 1465171.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-012619 20240930 Derivative Liabilities 401168.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender Five;
0001641172-25-012619 20240331 Income Tax Expense Benefit USD 1 us-gaap/2024
0001641172-25-012619 20240331 Increase Decrease In Accounts Payable 124.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240331 Increase Decrease In Unearned Premiums -78407.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240930 Liabilities 5378456.0000 USD 0 us-gaap/2024
0001641172-25-012619 20240930 Marketable Securities Current 17733.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-012619 20250331 Marketable Securities Current 17733.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-012619 20250331 Notes Payable Current 100000.0000 USD 0 us-gaap/2024 Debt Instrument= December Twenty Two Thousand Seventeen;
0001641172-25-012619 20250331 Notes Payable Current 59200.0000 USD 0 us-gaap/2024 Debt Instrument= Zander Therapeutics Inc; Related Party Transaction= Related Party;
0001641172-25-012619 20250331 Notes Payable Current 210363.0000 USD 0 us-gaap/2024 Related Party Transaction= Related Party;
0001641172-25-012619 20250331 Other Assets 17733.0000 USD 0 us-gaap/2024
0001641172-25-012619 20240331 Other Noncash Income Expense -21383.0000 USD 1 us-gaap/2024
0001641172-25-012619 20240331 Other Noncash Income Expense -43534.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240930 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-012619 20240930 Preferred Stock Shares Authorized 800000000.0000 shares 0 us-gaap/2024
0001641172-25-012619 20250331 Preferred Stock Shares Issued 34.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-012619 20250331 Preferred Stock Shares Outstanding 34.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-012619 20250331 Preferred Stock Value 3.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-012619 20240331 Proceeds From Issuance Of Common Stock 400234.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240331 Profit Loss -267386.0000 USD 2 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-012619 20250331 Research And Development Expense USD 2 us-gaap/2024
0001641172-25-012619 20250331 Revenue From Contract With Customer Excluding Assessed Tax 118130.0000 USD 2 us-gaap/2024
0001641172-25-012619 20230930 Shares Outstanding 409551.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240930 Shares Outstanding 10123771.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240930 Shares Outstanding 15007.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20230930 Stockholders Equity 40.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240331 Stockholders Equity 15044676.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-012619 20250331 Stockholders Equity -204847.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-012619 20250331 Stockholders Equity -20951859.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-012619 20241031 Stock Issued During Period Shares Issued For Services 370084.0000 shares 0 us-gaap/2024 Equity Components= Common Stock; Title Of Individual= Non Employee Service;
0001641172-25-012619 20250331 Stock Issued During Period Value Issued For Services 33715.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Stock Issued During Period Value Issued For Services USD 2 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20250331 Stock Issued During Period Value Issued For Services USD 2 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240331 Stock Issued During Period Value New Issues 400269.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Stock Issued During Period Value Other 20000.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Stock Issued During Period Value Other 50.0000 USD 2 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-012619 20250331 Stock Issued During Period Value Stock Dividend USD 2 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20250331 Weighted Average Number Of Diluted Shares Outstanding 18730773.0000 shares 2 us-gaap/2024
0001641172-25-012619 20250331 Accounts Payable Current 30563.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-011206 20240930 Accounts Receivable Net Current 94873.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-011206 20231231 Accumulated Other Comprehensive Income Unrealized Loss -204847.0000 USD 1 0001641172-25-011206 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-011206 20240930 Assets Current 143351.0000 USD 0 us-gaap/2024
0001641172-25-011206 20230930 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 121037.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Cash Paid For Interest USD 1 0001641172-25-011206
0001641172-25-011206 20241231 Common Stock Shares Issued 21554704.0000 shares 0 us-gaap/2024
0001641172-25-011206 20241231 Convertible Note Payable Current 744630.0000 USD 0 0001641172-25-011206 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-011206 20240930 Derivative Liabilities 200584.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender Four;
0001641172-25-011206 20241231 Derivative Liabilities 353535.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender Six;
0001641172-25-011206 20231231 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -144932.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Increase Decrease In Accrued Liabilities 42852.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Increase Decrease In Prepaid Expense -25023.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Interest Expense Nonoperating 25352.0000 USD 1 us-gaap/2024
0001641172-25-011206 20240930 Marketable Securities Current USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Related Party Transactions By Related Party= Related Party;
0001641172-25-011206 20231231 Net Income Loss USD 1 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20231231 Net Income Loss -144933.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-011206 20240930 Notes Payable Current 41708.0000 USD 0 us-gaap/2024 Related Party Transaction= Related Party;
0001641172-25-011206 20241231 Operating Expenses 120443.0000 USD 1 us-gaap/2024
0001641172-25-011206 20231231 Other Noncash Income Expense -22151.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001641172-25-011206 20240930 Preferred Stock Shares Authorized 739000000.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-011206 20240930 Preferred Stock Shares Outstanding 34.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-011206 20231231 Proceeds From Repayments Of Secured Debt -46500.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Retained Earnings Accumulated Deficit -20932504.0000 USD 0 us-gaap/2024
0001641172-25-011206 20231231 Revenue From Contract With Customer Excluding Assessed Tax 31640.0000 USD 1 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-011206 20230930 Stockholders Equity -5103999.0000 USD 0 us-gaap/2024
0001641172-25-011206 20230930 Stockholders Equity 40.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20230930 Stockholders Equity 352.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-011206 20231231 Stockholders Equity -5241483.0000 USD 0 us-gaap/2024
0001641172-25-011206 20231231 Stockholders Equity USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20231231 Stockholders Equity 3.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20231231 Stockholders Equity 376.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-011206 20241231 Stock Issued During Period Shares Other 500000.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-011206 20241231 Stock Issued During Period Value Issued For Services USD 1 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20231231 Stock Issued During Period Value New Issues 24.0000 USD 1 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-011206 20241231 Stock Issued During Period Value Other 19950.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-011206 20241231 Stock Issued During Period Value Stock Dividend USD 1 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Accounts Receivable Net Current 0.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-009968 20230930 Additional Paid In Capital 14644467.0000 USD 0 us-gaap/2024
0001641172-25-009968 20230930 Amortization Of Debt Discount Premium 864.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Assets 161084.0000 USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20240930 Assets -16527.0000 USD 0 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20230930 Common Shares Issued For Interest 25369.0000 USD 4 0001641172-25-009968
0001641172-25-009968 20240930 Common Stock Issued For Compensation 37463.0000 USD 4 0001641172-25-009968
0001641172-25-009968 20240930 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Common Stock Shares Outstanding 5258235.0000 shares 0 us-gaap/2024
0001641172-25-009968 20230930 Convertible Note Payable Current 499880.0000 USD 0 0001641172-25-009968 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-009968 20230930 Derivative Liabilities 200000.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender Four;
0001641172-25-009968 20230930 Derivative Liabilities 800000.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender One;
0001641172-25-009968 20240930 Derivative Liabilities 200584.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender Four;
0001641172-25-009968 20240930 Financing Fees USD 4 0001641172-25-009968 Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -668255.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Income Tax Expense Benefit USD 4 us-gaap/2024
0001641172-25-009968 20230930 Increase Decrease In Common Stock Issued For Expenses 250000.0000 USD 4 0001641172-25-009968
0001641172-25-009968 20240930 Liabilities And Stockholders Equity 177611.0000 USD 0 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Liabilities Current 6816.0000 USD 0 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Long Term Notes Payable USD 0 us-gaap/2024 Related Party Transaction= Nonrelated Party;
0001641172-25-009968 20240930 Long Term Notes Payable USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20240930 Marketable Securities Current USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Related Party Transactions By Related Party= Related Party;
0001641172-25-009968 20240930 Marketable Securities Current 17733.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party; Restatement= Restatement;
0001641172-25-009968 20230930 Net Income Loss USD 4 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Net Income Loss 1156507.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009968 20240930 Net Income Loss USD 4 us-gaap/2024 Class Of Stock= Preferred Stock Series N C; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Net Income Loss USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009968 20240630 Notes Payable Current 0.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Notes Payable Current 200000.0000 USD 0 us-gaap/2024 Debt Instrument= May Five Two Thousand Seventeen;
0001641172-25-009968 20240930 Notes Payable Current 41708.0000 USD 0 us-gaap/2024 Related Party Transaction= Related Party;
0001641172-25-009968 20240930 Notes Payable Current USD 0 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Operating Expenses 653781.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Operating Expenses 654747.0000 USD 4 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Preferred Shares Issued For Debt USD 4 0001641172-25-009968
0001641172-25-009968 20240930 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-009968 20240930 Preferred Stock Shares Authorized 600000.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-009968 20230930 Preferred Stock Shares Issued 15007.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-009968 20220930 Preferred Stock Shares Outstanding 34.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-009968 20240930 Preferred Stock Shares Outstanding 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-009968 20240930 Preferred Stock Value 1011.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Restatement= Restatement;
0001641172-25-009968 20240930 Proceeds From Issuance Of Common Stock 563722.0000 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Revenue From Contract With Customer Excluding Assessed Tax 110000.0000 USD 4 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-009968 20230930 Shares Outstanding 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stockholders Equity -5103999.0000 USD 0 us-gaap/2024
0001641172-25-009968 20230930 Stockholders Equity 40.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stockholders Equity USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Common Shares Issued For Financing Expenses USD 4 0001641172-25-009968 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Common Shares Issued For Financing Expenses 50.0000 USD 4 0001641172-25-009968 Equity Components= Common Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Issued For Services USD 4 us-gaap/2024 Class Of Stock= Preferred Stock Series N C; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Issued For Services USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Issued For Services 37463.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Stock Issued During Period Value Issued For Services USD 4 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value New Issues USD 4 us-gaap/2024 Class Of Stock= Preferred Stock Series N C; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value New Issues USD 4 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value New Issues USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009968 20241031 Stock Issued During Period Value New Issues 20000.0000 USD 0 us-gaap/2024 Subsequent Event Type= Subsequent Event;
0001641172-25-009968 20230930 Stock Issued During Period Value P Preferred Shares Issued For Interest USD 4 0001641172-25-009968 Class Of Stock= Preferred Stock Series N C; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Preferred Shares Issued For Dividend USD 4 0001641172-25-009968 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240930 Accrued Liabilities Current 1664827.0000 USD 0 us-gaap/2024
0001641172-25-012619 20250331 Accumulated Other Comprehensive Income Loss Net Of Tax -204847.0000 USD 0 us-gaap/2024
0001641172-25-012619 20240930 Additional Paid In Capital 15403050.0000 USD 0 us-gaap/2024
0001641172-25-012619 20240331 Amortization Of Financing Costs And Discounts 8706.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Assets 169482.0000 USD 0 us-gaap/2024
0001641172-25-012619 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 78114.0000 USD 0 us-gaap/2024
0001641172-25-012619 20240331 Common Shares Issued For Debt USD 2 0001641172-25-012619
0001641172-25-012619 20250331 Common Shares Issued For Debt 20000.0000 USD 2 0001641172-25-012619
0001641172-25-012619 20240930 Common Stock Value 527.0000 USD 0 us-gaap/2024
0001641172-25-012619 20250331 Derivative Liabilities 38617.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender Seven;
0001641172-25-012619 20250331 Earnings Per Share Basic -0.0300 USD 2 us-gaap/2024
0001641172-25-012619 20240331 Earnings Per Share Diluted -0.0300 USD 1 us-gaap/2024
0001641172-25-012619 20240331 Earnings Per Share Diluted -0.0700 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Income Tax Expense Benefit USD 2 us-gaap/2024
0001641172-25-012619 20250331 Increase Decrease In Accounts Payable 4034.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240331 Interest Expense Nonoperating 34828.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240331 Stock Issued During Period Shares New Issues 608256.0000 shares 2 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-012619 20250331 Liabilities Noncurrent USD 0 us-gaap/2024
0001641172-25-012619 20250331 Long Term Notes Payable USD 0 us-gaap/2024
0001641172-25-012619 20240930 Marketable Securities Current 6495.0000 USD 0 us-gaap/2024 Equity Components= Common Stock; Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-012619 20240930 Marketable Securities Current 17333.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-012619 20250331 Marketable Securities Current 11238.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-012619 20250331 Marketable Securities Current 6495.0000 USD 0 us-gaap/2024 Equity Components= Common Stock; Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-012619 20250331 Net Cash Provided By Used In Financing Activities 168655.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240331 Net Income Loss -122454.0000 USD 1 us-gaap/2024
0001641172-25-012619 20250331 Net Income Loss -534739.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240331 Net Income Loss Available To Common Stockholders Basic -122454.0000 USD 1 us-gaap/2024
0001641172-25-012619 20240930 Notes Payable Current 40000.0000 USD 0 us-gaap/2024 Debt Instrument= Zander Therapeutics Inc; Related Party Transaction= Related Party;
0001641172-25-012619 20250331 Notes Payable Current 100000.0000 USD 0 us-gaap/2024 Debt Instrument= March Eight Two Thousand Sixteen;
0001641172-25-012619 20250331 Operating Expenses 172414.0000 USD 1 us-gaap/2024
0001641172-25-012619 20250331 Operating Income Loss -113349.0000 USD 1 us-gaap/2024
0001641172-25-012619 20250331 Other Noncash Income Expense -360012.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240331 Preferred Shares Issued For Interest USD 2 0001641172-25-012619
0001641172-25-012619 20250331 Preferred Stock Shares Authorized 60000000.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-012619 20250331 Preferred Stock Shares Authorized 20000.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-012619 20240930 Preferred Stock Shares Issued 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-012619 20250331 Preferred Stock Shares Issued 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-012619 20250331 Preferred Stock Shares Issued 15007.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-012619 20250331 Preferred Stock Shares Outstanding 15007.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-012619 20240930 Preferred Stock Value 2.0000 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-012619 20250331 Preferred Stock Value 1011.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-012619 20240930 Prepaid Expense Current 47762.0000 USD 0 us-gaap/2024
0001641172-25-012619 20250331 Proceeds From Repayments Of Secured Debt USD 2 us-gaap/2024
0001641172-25-012619 20240331 Rental Expense 32215.0000 USD 2 0001641172-25-012619
0001641172-25-012619 20240930 Shares Outstanding 34.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240930 Stockholders Equity -5217372.0000 USD 0 us-gaap/2024
0001641172-25-012619 20240930 Stockholders Equity -20417118.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-012619 20250331 Stockholders Equity 15455134.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-012619 20250331 Stock Issued During Period Shares Issued For Services 370084.0000 shares 2 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-012619 20240331 Stock Issued During Period Value New Issues 61.0000 USD 2 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-012619 20240331 Stock Issued During Period Value New Issues USD 2 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-012619 20250331 Stock Issued During Period Value Other USD 2 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20250331 Stock Issued During Period Value Stock Dividend 0.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Stock Issued During Period Value Stock Dividend USD 2 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20250331 Stock Issued During Period Value Stock Dividend USD 2 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-012619 20180531 Unrealized Gain Loss On Investments -81112.0000 USD 0 us-gaap/2024 Equity Components= Common Stock; Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-009968 20230930 Accrued Liabilities Current 1644882.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Accrued Liabilities Current 1707680.0000 USD 0 us-gaap/2024
0001641172-25-011206 20240930 Additional Paid In Capital 15403050.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Accounts Receivable Net Current 122298.0000 USD 0 us-gaap/2024
0001641172-25-011206 20240930 Accrued Liabilities Current 1664827.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Common Shares Issued For Interest USD 1 0001641172-25-011206
0001641172-25-011206 20241231 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Common Stock Shares Authorized 5800000000.0000 shares 0 us-gaap/2024
0001641172-25-011206 20241231 Common Stock Shares Outstanding 21554704.0000 shares 0 us-gaap/2024
0001641172-25-011206 20241231 Common Stock Value 2157.0000 USD 0 us-gaap/2024
0001641172-25-011206 20240930 Convertible Note Payable Current USD 0 0001641172-25-011206 Related Party Transactions By Related Party= Related Party;
0001641172-25-011206 20241231 Derivative Liabilities 199147.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender Four;
0001641172-25-011206 20241231 Derivative Liabilities 796586.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender One;
0001641172-25-011206 20231231 Earnings Per Share Basic -0.0400 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Increase Decrease In Accounts Payable 6336.0000 USD 1 us-gaap/2024
0001641172-25-011206 20231231 Increase Decrease In Prepaid Expense -5000.0000 USD 1 us-gaap/2024
0001641172-25-011206 20231231 Increase Decrease In Unearned Premiums -46767.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Increase Decrease In Unearned Premiums -31640.0000 USD 1 us-gaap/2024
0001641172-25-011206 20240930 Marketable Securities Current 6495.0000 USD 0 us-gaap/2024 Equity Components= Common Stock; Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-011206 20241231 Marketable Securities Current USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Related Party Transactions By Related Party= Related Party;
0001641172-25-011206 20231231 Net Cash Provided By Used In Operating Activities -162336.0000 USD 1 us-gaap/2024
0001641172-25-011206 20231231 Net Income Loss Available To Common Stockholders Basic -144913.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Notes Payable Current 1708.0000 USD 0 us-gaap/2024 Debt Instrument= David Koos; Related Party Transaction= Related Party;
0001641172-25-011206 20241231 Notes Payable Current 25000.0000 USD 0 us-gaap/2024 Debt Instrument= Guaranted Interest;
0001641172-25-011206 20241231 Notes Payable Current 107507.0000 USD 0 us-gaap/2024 Related Party Transaction= Related Party;
0001641172-25-011206 20231231 Operating Income Loss -122782.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Other Liabilities Current 21000.0000 USD 0 us-gaap/2024
0001641172-25-011206 20240930 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Shares Authorized 739000000.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-011206 20240930 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0001641172-25-011206 20240930 Preferred Stock Shares Issued 409551.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-011206 20240930 Preferred Stock Shares Outstanding 409551.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Shares Outstanding 34.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-011206 20240930 Preferred Stock Value 2.0000 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-011206 20211231 Rental Expense 5000.0000 USD 0 0001641172-25-011206
0001641172-25-011206 20241231 Revenue From Contract With Customer Excluding Assessed Tax 31640.0000 USD 1 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-011206 20241231 Revenue From Contract With Customer Excluding Assessed Tax 27425.0000 USD 1 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-011206 20230930 Shares Outstanding 3506366.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-011206 20231231 Stockholders Equity 40.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20240930 Stockholders Equity -5217372.0000 USD 0 us-gaap/2024
0001641172-25-011206 20240930 Stockholders Equity -20417118.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-011206 20241231 Stockholders Equity USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20241231 Stockholders Equity 1011.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20241231 Stockholders Equity 2157.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-011206 20241231 Stock Issued During Period Shares Issued For Services 370084.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-011206 20241231 Stock Issued During Period Value Issued For Services 37.0000 USD 1 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-011206 20231231 Stock Issued During Period Value New Issues USD 1 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20241231 Stock Issued During Period Value Stock Dividend 0.0000 USD 1 us-gaap/2024
0001641172-25-011206 20231231 Unrealized Gain Loss On Investments USD 1 us-gaap/2024
0001641172-25-012619 20250331 Interest Expense Nonoperating 47681.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Rental Expense 22500.0000 USD 1 0001641172-25-012619
0001641172-25-012619 20240331 Accumulated Other Comprehensive Income Unrealized Loss -204847.0000 USD 2 0001641172-25-012619
0001641172-25-012619 20240331 Amortization Of Debt Discount Premium 8706.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Amortization Of Debt Discount Premium 25278.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240930 Assets 161084.0000 USD 0 us-gaap/2024
0001641172-25-012619 20250331 Assets Current 151749.0000 USD 0 us-gaap/2024
0001641172-25-012619 20250331 Cash 1761.0000 USD 0 us-gaap/2024
0001641172-25-012619 20240930 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001641172-25-012619 20240930 Common Stock Shares Authorized 5800000000.0000 shares 0 us-gaap/2024
0001641172-25-012619 20250331 Common Stock Shares Authorized 5800000000.0000 shares 0 us-gaap/2024
0001641172-25-012619 20250331 Common Stock Value 2157.0000 USD 0 us-gaap/2024
0001641172-25-012619 20250331 Deferred Revenue Current 1401891.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-012619 20240331 Derivative Gain Loss On Derivative Net USD 1 us-gaap/2024
0001641172-25-012619 20250331 Derivative Gain Loss On Derivative Net -287053.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240930 Derivative Liabilities USD 0 us-gaap/2024 Derivative Instrument Risk= Lender Six;
0001641172-25-012619 20250331 Earnings Per Share Basic 0.0000 USD 1 us-gaap/2024
0001641172-25-012619 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -19354.0000 USD 1 us-gaap/2024
0001641172-25-012619 20240331 Increase Decrease In Accounts Receivable 39723.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240331 Increase Decrease In Accrued Liabilities -171.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Increase Decrease In Derivative Liabilities 287053.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240930 Marketable Securities Current USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Related Party Transactions By Related Party= Related Party;
0001641172-25-012619 20250331 Marketable Securities Current USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Related Party Transactions By Related Party= Related Party;
0001641172-25-012619 20250331 Marketable Securities Current 17733.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Related Party Transactions By Related Party= Related Party;
0001641172-25-012619 20240930 Notes Payable Current USD 0 us-gaap/2024 Debt Instrument= B S T Partners; Related Party Transaction= Related Party;
0001641172-25-012619 20240930 Notes Payable Current 41708.0000 USD 0 us-gaap/2024 Related Party Transaction= Related Party;
0001641172-25-012619 20250331 Notes Payable Current 25000.0000 USD 0 us-gaap/2024 Debt Instrument= Guaranted Interest;
0001641172-25-012619 20240331 Operating Expenses 341982.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240331 Operating Income Loss -101071.0000 USD 1 us-gaap/2024
0001641172-25-012619 20250331 Other Liabilities Current 21000.0000 USD 0 us-gaap/2024
0001641172-25-012619 20240331 Preferred Shares Issued For Debt USD 2 0001641172-25-012619
0001641172-25-012619 20240930 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-012619 20250331 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-012619 20250331 Preferred Stock Shares Authorized 739000000.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-012619 20250331 Preferred Stock Shares Outstanding 10123771.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-012619 20250331 Prepaid Expense Current 265.0000 USD 0 us-gaap/2024
0001641172-25-012619 20250331 Proceeds From Repayments Of Notes Payable 168655.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240331 Research And Development Expense 40133.0000 USD 1 us-gaap/2024
0001641172-25-012619 20240331 Revenue From Contract With Customer Excluding Assessed Tax 63280.0000 USD 2 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-012619 20240331 Revenue From Contract With Customer Excluding Assessed Tax 54849.0000 USD 2 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-012619 20250331 Revenue From Contract With Customer Excluding Assessed Tax 31640.0000 USD 1 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-012619 20250331 Revenue From Contract With Customer Excluding Assessed Tax 27425.0000 USD 1 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-012619 20230930 Shares Outstanding 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240331 Shares Outstanding 4114622.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-012619 20240930 Shares Outstanding 5258235.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-012619 20230930 Stockholders Equity -5103999.0000 USD 0 us-gaap/2024
0001641172-25-012619 20230930 Stockholders Equity 2.0000 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240331 Stockholders Equity 3.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240331 Stockholders Equity 413.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-012619 20240930 Stockholders Equity USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240930 Stockholders Equity 1011.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20250331 Stockholders Equity -5698399.0000 USD 0 us-gaap/2024
0001641172-25-012619 20250331 Stockholders Equity USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20250331 Stockholders Equity 1011.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20250331 Stockholders Equity 2157.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-012619 20240331 Stock Issued During Period Value New Issues USD 2 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240331 Stock Issued During Period Value New Issues USD 2 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-012619 20250331 Stock Issued During Period Value Other USD 2 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20250331 Stock Issued During Period Value Other USD 2 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20250331 Stock Issued During Period Value Stock Dividend USD 2 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20181130 Unrealized Gain Loss On Investments -123733.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-012619 20250331 Weighted Average Number Of Shares Outstanding Basic 18730773.0000 shares 2 us-gaap/2024
0001641172-25-009968 20240930 Amortization Of Financing Costs And Discounts -28998.0000 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Assets Current 131037.0000 USD 0 us-gaap/2024
0001641172-25-009968 20230930 Common Stock Issued For Compensation USD 4 0001641172-25-009968
0001641172-25-009968 20220930 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001641172-25-009968 20230930 Common Stock Shares Authorized 5800000000.0000 shares 0 us-gaap/2024
0001641172-25-009968 20220930 Common Stock Shares Issued 3354866.0000 shares 0 us-gaap/2024
0001641172-25-009968 20240930 Convertible Note Payable Current USD 0 0001641172-25-009968 Related Party Transactions By Related Party= Nonrelated Party; Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Convertible Note Payable Current 499880.0000 USD 0 0001641172-25-009968 Related Party Transactions By Related Party= Nonrelated Party; Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Deferred Revenue Current USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party; Restatement= Restatement;
0001641172-25-009968 20240930 Deferred Revenue Current USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party; Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Derivative Liabilities 1404090.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Earnings Per Share Basic -0.1600 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Fair Value Adjustment Of Warrants -2151755.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Increase Decrease In Accrued Liabilities 19946.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Increase Decrease In Prepaid Expense 37762.0000 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Interest Expense Nonoperating 58584.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Interest Expense Nonoperating USD 4 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Liabilities And Stockholders Equity -221374.0000 USD 0 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20230930 Marketable Securities Current USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Related Party Transactions By Related Party= Related Party;
0001641172-25-009968 20240930 Marketable Securities Current USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party; Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Marketable Securities Current 17733.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party; Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Marketable Securities Current 17733.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-009968 20240930 Net Income Loss -809255.0000 USD 4 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Notes Payable Current 50000.0000 USD 0 us-gaap/2024 Debt Instrument= October Thirty One Two Thousand Sixteen;
0001641172-25-009968 20230930 Operating Income Loss -686950.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Other Assets 17733.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Other Assets 17733.0000 USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20230930 Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax 0.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Other Liabilities Current 21000.0000 USD 0 us-gaap/2024
0001641172-25-009968 20230930 Preferred Shares Distributed As Dividend USD 4 0001641172-25-009968
0001641172-25-009968 20230930 Preferred Stock Shares Authorized 60000000.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-009968 20230930 Preferred Stock Shares Authorized 20000.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-009968 20230930 Preferred Stock Shares Issued 34.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-009968 20230930 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0001641172-25-009968 20230930 Preferred Stock Shares Outstanding 15007.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-009968 20240930 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Preferred Stock;
0001641172-25-009968 20240930 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-009968 20240930 Preferred Stock Value 1011.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Preferred Stock Value 3.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-009968 20240930 Preferred Stock Value 2.0000 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Restatement= Restatement;
0001641172-25-009968 20230930 Professional Fees 606237.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Professional Fees 364927.0000 USD 4 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Research And Development Expense 153685.0000 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Revenue From Contract With Customer Excluding Assessed Tax 126560.0000 USD 4 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-009968 20240930 Revenue From Contract With Customer Excluding Assessed Tax USD 4 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party; Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Revenue From Contract With Customer Excluding Assessed Tax 126560.0000 USD 4 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party; Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Revenue From Contract With Customer Excluding Assessed Tax 110000.0000 USD 4 us-gaap/2024 Related Party Transactions By Related Party= Related Party; Restatement= Scenario Previously Reported;
0001641172-25-009968 20230930 Shares Outstanding 34.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20220930 Stockholders Equity USD 0 us-gaap/2024 Class Of Stock= Preferred Stock Series N C; Equity Components= Preferred Stock;
0001641172-25-009968 20220930 Stockholders Equity 28.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20220930 Stockholders Equity 3.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20220930 Stockholders Equity 336.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009968 20240930 Stockholders Equity 15403050.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009968 20240930 Stock Issued During Period Shares New Issues 1001954.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009968 20230930 Stock Issued During Period Shares Preferred Shares Issued For Debt 70114.0000 shares 4 0001641172-25-009968 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Common Shares Issued For Financing Expenses 13.0000 USD 4 0001641172-25-009968 Equity Components= Common Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Common Shares Issued For Financing Expenses USD 4 0001641172-25-009968 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Issued For Services USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009968 20230930 Stock Issued During Period Value Issued For Services One USD 4 0001641172-25-009968 Class Of Stock= Preferred Stock Series N C; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Issued For Services One USD 4 0001641172-25-009968 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Issued For Services One USD 4 0001641172-25-009968 Equity Components= Retained Earnings;
0001641172-25-009968 20230930 Stock Issued During Period Value Other USD 4 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Other 25368.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009968 20230930 Stock Issued During Period Value P Preferred Shares Issued For Interest 380258.0000 USD 4 0001641172-25-009968 Equity Components= Additional Paid In Capital;
0001641172-25-009968 20230930 Stock Issued During Period Value Preferred Shares Issued For Accrued Salaries 10050.0000 USD 4 0001641172-25-009968
0001641172-25-009968 20230930 Stock Issued During Period Value Preferred Shares Issued For Accrued Salaries USD 4 0001641172-25-009968 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Preferred Shares Issued For Accrued Salaries USD 4 0001641172-25-009968 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Preferred Shares Issued For Accrued Salaries 10048.0000 USD 4 0001641172-25-009968 Equity Components= Additional Paid In Capital;
0001641172-25-009968 20230930 Stock Issued During Period Value Preferred Shares Issued For Debt USD 4 0001641172-25-009968 Class Of Stock= Preferred Stock Series N C; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Preferred Shares Issued For Debt 761493.0000 USD 4 0001641172-25-009968 Equity Components= Additional Paid In Capital;
0001641172-25-009968 20240930 Stock Issued During Period Value Preferred Shares Issued For Services 2.0000 USD 4 0001641172-25-009968 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Reverse Stock Splits USD 4 0001641172-25-009968 Equity Components= Retained Earnings;
0001641172-25-012619 20240331 Amortization Of Debt Discount Premium 4339.0000 USD 1 us-gaap/2024
0001641172-25-012619 20240930 Accounts Payable Current 29669.0000 USD 0 us-gaap/2024
0001641172-25-012619 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 1761.0000 USD 0 us-gaap/2024
0001641172-25-012619 20250331 Cash Paid For Interest USD 2 0001641172-25-012619
0001641172-25-012619 20240331 Common Shares Issued For Interest USD 2 0001641172-25-012619
0001641172-25-012619 20240930 Common Stock Shares Outstanding 5258235.0000 shares 0 us-gaap/2024
0001641172-25-012619 20240331 Derivative Gain Loss On Derivative Net USD 2 us-gaap/2024
0001641172-25-012619 20240930 Derivative Liabilities 200584.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender Four;
0001641172-25-012619 20250331 General And Administrative Expense 26665.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Marketable Securities Current USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Related Party Transactions By Related Party= Related Party;
0001641172-25-012619 20240331 Net Cash Provided By Used In Operating Activities -371658.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Net Income Loss -19354.0000 USD 1 us-gaap/2024
0001641172-25-012619 20250331 Net Income Loss Available To Common Stockholders Basic -19354.0000 USD 1 us-gaap/2024
0001641172-25-012619 20240331 Operating Expenses 160135.0000 USD 1 us-gaap/2024
0001641172-25-012619 20250331 Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax 0.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240930 Other Liabilities Current 21000.0000 USD 0 us-gaap/2024
0001641172-25-012619 20250331 Other Noncash Income Expense 93995.0000 USD 1 us-gaap/2024
0001641172-25-012619 20250331 Preferred Stock Shares Authorized 800000000.0000 shares 0 us-gaap/2024
0001641172-25-012619 20240930 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Preferred Stock;
0001641172-25-012619 20240930 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-012619 20250331 Proceeds From Issuance Of Common Stock USD 2 us-gaap/2024
0001641172-25-012619 20240331 Professional Fees 93400.0000 USD 1 us-gaap/2024
0001641172-25-012619 20250331 Retained Earnings Accumulated Deficit -20951859.0000 USD 0 us-gaap/2024
0001641172-25-012619 20250331 Shares Outstanding 10123771.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20250331 Shares Outstanding 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240930 Stockholders Equity -204847.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-012619 20250331 Stockholders Equity 2.0000 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20250331 Stock Issued During Period Shares Other 500000.0000 shares 2 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-012619 20240331 Stock Issued During Period Value New Issues USD 2 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240331 Stock Issued During Period Value New Issues USD 2 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240331 Stock Issued During Period Value New Issues 400209.0000 USD 2 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-012619 20250331 Stock Issued During Period Value Other USD 2 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20250331 Stock Issued During Period Value Stock Dividend USD 2 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20231231 Amortization Of Financing Costs And Discounts 4367.0000 USD 1 us-gaap/2024
0001641172-25-011206 20240930 Common Stock Shares Outstanding 3750565.0000 shares 0 us-gaap/2024
0001641172-25-011206 20240930 Convertible Note Payable Current 499880.0000 USD 0 0001641172-25-011206 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-011206 20240930 Derivative Liabilities 1404090.0000 USD 0 us-gaap/2024
0001641172-25-011206 20240930 Derivative Liabilities 802337.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender One;
0001641172-25-011206 20241231 Earnings Per Share Diluted -0.1300 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -515384.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Liabilities 5870459.0000 USD 0 us-gaap/2024
0001641172-25-011206 20240930 Marketable Securities Current 17333.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-011206 20231231 Net Cash Provided By Used In Financing Activities 165797.0000 USD 1 us-gaap/2024
0001641172-25-011206 20231231 Net Income Loss USD 1 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20231231 Net Income Loss USD 1 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20241231 Net Income Loss -515385.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Net Income Loss USD 1 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20240930 Preferred Stock Shares Issued 15007.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Shares Issued 10123771.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0001641172-25-011206 20231231 Proceeds From Issuance Of Common Stock 212297.0000 USD 1 us-gaap/2024
0001641172-25-011206 20240930 Retained Earnings Accumulated Deficit -20417118.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Revenue From Contract With Customer Excluding Assessed Tax 59065.0000 USD 1 us-gaap/2024
0001641172-25-011206 20230930 Shares Outstanding 409551.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20231231 Shares Outstanding 3750565.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-011206 20240930 Shares Outstanding 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20241231 Shares Outstanding 21554704.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-011206 20240930 Stockholders Equity 2.0000 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20240930 Stockholders Equity 527.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-011206 20241231 Stockholders Equity 3.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20231231 Stock Issued During Period Value New Issues USD 1 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20231231 Stock Issued During Period Value New Issues 212272.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-011206 20241231 Stock Issued During Period Value Stock Dividend -1543.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-011206 20241231 Stock Issued During Period Value Stock Dividend USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-011206 20180531 Unrealized Gain Loss On Investments -81112.0000 USD 0 us-gaap/2024 Equity Components= Common Stock; Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-011206 20231231 Weighted Average Number Of Diluted Shares Outstanding 3596027.0000 shares 1 us-gaap/2024
0001641172-25-011206 20241231 Accounts Payable Current 36005.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Accounts Payable Current 30563.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-011206 20241231 Amortization Of Financing Costs And Discounts 12639.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Assets Current 173683.0000 USD 0 us-gaap/2024
0001641172-25-011206 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 3460.0000 USD 1 us-gaap/2024
0001641172-25-011206 20240930 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Convertible Note Payable Current USD 0 0001641172-25-011206 Related Party Transactions By Related Party= Related Party;
0001641172-25-011206 20231231 Derivative Gain Loss On Derivative Net USD 1 us-gaap/2024
0001641172-25-011206 20240930 Derivative Liabilities USD 0 us-gaap/2024 Derivative Instrument Risk= Lender Seven;
0001641172-25-011206 20240930 Derivative Liabilities USD 0 us-gaap/2024 Derivative Instrument Risk= Lender Six;
0001641172-25-011206 20241231 General And Administrative Expense 13317.0000 USD 1 us-gaap/2024
0001641172-25-011206 20231231 Income Tax Expense Benefit USD 1 us-gaap/2024
0001641172-25-011206 20241231 Liabilities Current 5870459.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Liabilities Noncurrent USD 0 us-gaap/2024
0001641172-25-011206 20241231 Marketable Securities Current 11238.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-011206 20241231 Marketable Securities Current 6495.0000 USD 0 us-gaap/2024 Equity Components= Common Stock; Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-011206 20241231 Marketable Securities Current 17733.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-011206 20241231 Net Cash Provided By Used In Operating Activities -66379.0000 USD 1 us-gaap/2024
0001641172-25-011206 20231231 Net Income Loss USD 1 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20240930 Notes Payable Current 100000.0000 USD 0 us-gaap/2024 Debt Instrument= December Twenty Two Thousand Seventeen;
0001641172-25-011206 20241231 Other Noncash Income Expense -454007.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Preferred Shares Issued For Interest USD 1 0001641172-25-011206
0001641172-25-011206 20240930 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-011206 20240930 Preferred Stock Shares Authorized 600000.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Shares Authorized 60000000.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Shares Issued 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Shares Issued 15007.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-011206 20240930 Preferred Stock Shares Outstanding 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-011206 20241231 Prepaid Expense Current 51250.0000 USD 0 us-gaap/2024
0001641172-25-011206 20231231 Professional Fees 106900.0000 USD 1 us-gaap/2024
0001641172-25-011206 20231231 Revenue From Contract With Customer Excluding Assessed Tax 59065.0000 USD 1 us-gaap/2024
0001641172-25-011206 20231231 Revenue From Contract With Customer Excluding Assessed Tax 27425.0000 USD 1 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-011206 20230930 Shares Outstanding 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20231231 Shares Outstanding 409551.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20230930 Stockholders Equity 2.0000 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20240930 Stockholders Equity USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20241231 Stockholders Equity -20932504.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-011206 20231231 Stock Issued During Period Value New Issues USD 1 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20241231 Stock Issued During Period Value Stock Dividend USD 1 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-011206 20241231 Stock Issued During Period Value Stock Dividend 1543.0000 USD 1 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-011206 20241231 Unrealized Gain Loss On Investments USD 1 us-gaap/2024
0001641172-25-011206 20240930 Accounts Receivable Net Current 94873.0000 USD 0 us-gaap/2024
0001641172-25-011206 20231231 Accumulated Other Comprehensive Income Unrealized Loss USD 1 0001641172-25-011206 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20240930 Cash And Cash Equivalents At Carrying Value 716.0000 USD 0 us-gaap/2024
0001641172-25-011206 20240930 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 716.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Common Stock Issued For Compensation 5203.0000 USD 1 0001641172-25-011206
0001641172-25-011206 20240930 Common Stock Shares Authorized 5800000000.0000 shares 0 us-gaap/2024
0001641172-25-011206 20240930 Common Stock Value 527.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Deferred Revenue Current 1433531.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-011206 20241231 Derivative Gain Loss On Derivative Net -416016.0000 USD 1 us-gaap/2024
0001641172-25-011206 20231231 Increase Decrease In Accounts Receivable 12298.0000 USD 1 us-gaap/2024
0001641172-25-011206 20231231 Increase Decrease In Accrued Liabilities 17765.0000 USD 1 us-gaap/2024
0001641172-25-011206 20240930 Long Term Notes Payable USD 0 us-gaap/2024
0001641172-25-011206 20240930 Marketable Securities Current 11238.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-011206 20240930 Marketable Securities Current USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Related Party Transactions By Related Party= Related Party;
0001641172-25-011206 20240930 Marketable Securities Current 17733.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Related Party Transactions By Related Party= Related Party;
0001641172-25-011206 20241231 Marketable Securities Current 17733.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Related Party Transactions By Related Party= Related Party;
0001641172-25-011206 20240930 Notes Payable Current USD 0 us-gaap/2024 Debt Instrument= B S T Partners; Related Party Transaction= Related Party;
0001641172-25-011206 20241231 Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax 0.0000 USD 1 us-gaap/2024
0001641172-25-011206 20240930 Other Liabilities Current 21000.0000 USD 0 us-gaap/2024
0001641172-25-011206 20240930 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-011206 20240930 Preferred Stock Shares Authorized 20000.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Shares Authorized 20000.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0001641172-25-011206 20240930 Preferred Stock Shares Outstanding 15007.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Shares Outstanding 10123771.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Shares Outstanding 15007.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-011206 20240930 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Preferred Stock;
0001641172-25-011206 20240930 Preferred Stock Value 3.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Value 1011.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Value 2.0000 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-011206 20240930 Prepaid Expense Current 47762.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Proceeds From Repayments Of Secured Debt 65799.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Rental Expense 22500.0000 USD 1 0001641172-25-011206
0001641172-25-011206 20231231 Research And Development Expense 47528.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Share Based Compensation USD 1 us-gaap/2024
0001641172-25-011206 20231231 Shares Outstanding 34.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20241231 Shares Outstanding 34.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20230930 Stockholders Equity USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20230930 Stockholders Equity -19748863.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-011206 20231231 Stockholders Equity -204847.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-011206 20231231 Stockholders Equity -19893796.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-011206 20240930 Stockholders Equity 1011.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20240930 Stockholders Equity -204847.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-011206 20240930 Stockholders Equity 15403050.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-011206 20231231 Stock Issued During Period Value New Issues USD 1 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20241231 Stock Issued During Period Value Other USD 1 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20241231 Stock Issued During Period Value Stock Dividend USD 1 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20241231 Stock Issued During Period Value Stock Dividend USD 1 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20231231 Weighted Average Number Of Shares Outstanding Basic 3596027.0000 shares 1 us-gaap/2024
0001641172-25-011206 20241231 Weighted Average Number Of Shares Outstanding Basic 4110265.0000 shares 1 us-gaap/2024
0001641172-25-009968 20230930 Accounts Receivable Net Current 0.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Accounts Receivable Net Current 94873.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-009968 20240930 Accumulated Other Comprehensive Income Loss Net Of Tax -204847.0000 USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20240930 Assets Current 143351.0000 USD 0 us-gaap/2024
0001641172-25-009968 20230930 Cash And Cash Equivalents At Carrying Value 121037.0000 USD 0 us-gaap/2024
0001641172-25-009968 20220930 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 51204.0000 USD 0 us-gaap/2024
0001641172-25-009968 20230930 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 121037.0000 USD 0 us-gaap/2024
0001641172-25-009968 20230930 Common Stock Shares Issued 3506366.0000 shares 0 us-gaap/2024
0001641172-25-009968 20240930 Convertible Note Payable Current 499880.0000 USD 0 0001641172-25-009968 Related Party Transactions By Related Party= Nonrelated Party; Restatement= Restatement;
0001641172-25-009968 20240930 Convertible Note Payable Current USD 0 0001641172-25-009968 Related Party Transactions By Related Party= Related Party; Restatement= Restatement;
0001641172-25-009968 20240930 Convertible Note Payable Current USD 0 0001641172-25-009968 Related Party Transactions By Related Party= Related Party; Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Deferred Revenue Current USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party; Restatement= Restatement Adjustment;
0001641172-25-009968 20230930 Derivative Liabilities 1400000.0000 USD 0 us-gaap/2024
0001641172-25-009968 20230930 Derivative Liabilities 400000.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender Five;
0001641172-25-009968 20240930 Derivative Liabilities 1397274.0000 USD 0 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Earnings Per Share Diluted -0.1600 USD 4 us-gaap/2024
0001641172-25-009968 20230930 General And Administrative Expense 44975.0000 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Increase Decrease In Prepaid Expense -20947.0000 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Liabilities Current 5308002.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Liabilities Current 5378456.0000 USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20240930 Liabilities Noncurrent USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20230930 Long Term Notes Payable 149613.0000 USD 0 us-gaap/2024 Related Party Transaction= Nonrelated Party;
0001641172-25-009968 20240930 Long Term Notes Payable USD 0 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20230930 Marketable Securities Current 222580.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Related Party Transactions By Related Party= Related Party;
0001641172-25-009968 20230930 Marketable Securities Current 222579.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-009968 20230930 Net Income Loss 1156507.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Net Income Loss 198995.0000 USD 4 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20230930 Notes Payable Current 710.0000 USD 0 us-gaap/2024 Related Party Transaction= Related Party;
0001641172-25-009968 20240930 Notes Payable Current 100000.0000 USD 0 us-gaap/2024 Debt Instrument= December Twenty Two Thousand Seventeen;
0001641172-25-009968 20240930 Other Assets 17733.0000 USD 0 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20220930 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-009968 20220930 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-009968 20230930 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001641172-25-009968 20230930 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-009968 20220930 Preferred Stock Shares Authorized 800000000.0000 shares 0 us-gaap/2024
0001641172-25-009968 20240930 Preferred Stock Shares Authorized 739000000.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-009968 20230930 Preferred Stock Shares Issued 409551.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-009968 20220930 Preferred Stock Shares Outstanding 293033.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-009968 20230930 Preferred Stock Shares Outstanding 409551.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-009968 20240930 Preferred Stock Shares Outstanding 34.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-009968 20240930 Preferred Stock Shares Outstanding 10123771.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-009968 20230930 Preferred Stock Value 2.0000 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-009968 20240930 Research And Development Expense USD 4 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Revenue From Contract With Customer Excluding Assessed Tax 236560.0000 USD 4 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20220930 Shares Outstanding 293053.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20220930 Stockholders Equity USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stockholders Equity 352.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009968 20240930 Stockholders Equity -5194030.0000 USD 0 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20230930 Stock Issued During Period Preferred Shares Issued For Services 1112.0000 shares 4 0001641172-25-009968 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Common Shares Issued For Financing Expenses USD 4 0001641172-25-009968 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Common Shares Issued For Financing Expenses USD 4 0001641172-25-009968 Class Of Stock= Preferred Stock Series N C; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Issued For Services 1.0000 USD 4 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Issued For Services 37438.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009968 20240930 Stock Issued During Period Value Issued For Services 25.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Preferred Shares Issued For Accrued Salaries USD 4 0001641172-25-009968 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Preferred Shares Issued For Debt USD 4 0001641172-25-009968 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Preferred Shares Issued For Debt USD 4 0001641172-25-009968 Equity Components= Retained Earnings;
0001641172-25-009968 20240930 Stock Issued During Period Value Preferred Shares Issued For Dividend USD 4 0001641172-25-009968
0001641172-25-009968 20240930 Stock Issued During Period Value Preferred Shares Issued For Dividend -969.0000 USD 4 0001641172-25-009968 Equity Components= Additional Paid In Capital;
0001641172-25-009968 20240930 Stock Issued During Period Value Preferred Shares Issued For Services USD 4 0001641172-25-009968 Class Of Stock= Preferred Stock Series N C; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Preferred Shares Issued For Services USD 4 0001641172-25-009968 Equity Components= Common Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Preferred Shares Issued For Services USD 4 0001641172-25-009968 Equity Components= Retained Earnings;
0001641172-25-009968 20230930 Stock Issued During Period Value Reverse Stock Splits USD 4 0001641172-25-009968 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Accounts Payable Current 29668.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Accounts Receivable Net Current USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party; Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Accounts Receivable Net Current 94873.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party; Restatement= Scenario Previously Reported;
0001641172-25-009968 20230930 Other Assets 222580.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Accumulated Other Comprehensive Income Unrealized Loss -204847.0000 USD 4 0001641172-25-009968
0001641172-25-009968 20240930 Additional Paid In Capital 14666724.0000 USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20230930 Amortization Of Financing Costs And Discounts 864.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Cash And Cash Equivalents At Carrying Value 716.0000 USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20240930 Cash And Cash Equivalents At Carrying Value 716.0000 USD 0 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -120321.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Common Stock Value 527.0000 USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20240930 Convertible Note Payable Current USD 0 0001641172-25-009968 Related Party Transactions By Related Party= Related Party;
0001641172-25-009968 20240930 Convertible Note Payable Current USD 0 0001641172-25-009968 Related Party Transactions By Related Party= Related Party; Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Deferred Revenue Current USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party; Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Derivative Liabilities 802337.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender One;
0001641172-25-009968 20240930 Derivative Liabilities 6816.0000 USD 0 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20230930 Earnings Per Share Diluted 0.2900 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Financing Fees 145500.0000 USD 4 0001641172-25-009968
0001641172-25-009968 20240930 General And Administrative Expense 58920.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Liabilities And Stockholders Equity 161084.0000 USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20230930 Liabilities Noncurrent 149614.0000 USD 0 us-gaap/2024
0001641172-25-009968 20230930 Marketable Securities Current 87608.0000 USD 0 us-gaap/2024 Equity Components= Common Stock; Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-009968 20230930 Net Income Loss USD 4 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Net Income Loss USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009968 20240930 Net Income Loss USD 4 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Net Income Loss Available To Common Stockholders Basic 1023508.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Notes Payable Current 293819.0000 USD 0 us-gaap/2024 Related Party Transaction= Nonrelated Party;
0001641172-25-009968 20240930 Notes Payable Current 293819.0000 USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20230930 Other Noncash Income Expense 1843456.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Other Noncash Income Expense 198030.0000 USD 4 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20230930 Preferred Shares Issued For Debt 761500.0000 USD 4 0001641172-25-009968
0001641172-25-009968 20240930 Preferred Shares Issued For Interest USD 4 0001641172-25-009968
0001641172-25-009968 20230930 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-009968 20220930 Preferred Stock Shares Authorized 20000.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-009968 20230930 Preferred Stock Shares Authorized 600000.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-009968 20230930 Preferred Stock Shares Authorized 739000000.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-009968 20230930 Preferred Stock Shares Outstanding 34.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-009968 20230930 Preferred Stock Shares Outstanding 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-009968 20230930 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-009968 20240930 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Preferred Stock Value 3.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Proceeds From Notes Payable 77493.0000 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Proceeds From Repayments Of Secured Debt USD 4 us-gaap/2024
0001641172-25-009968 20240930 Professional Fees -966.0000 USD 4 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Rental Expense USD 4 0001641172-25-009968 Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Research And Development Expense 153685.0000 USD 4 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Retained Earnings Accumulated Deficit -20417118.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Revenue From Contract With Customer Excluding Assessed Tax USD 4 us-gaap/2024 Related Party Transactions By Related Party= Related Party; Restatement= Restatement Adjustment;
0001641172-25-009968 20230930 Shares Outstanding 409551.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Shares Outstanding 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20220930 Stockholders Equity -20905370.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009968 20240930 Stockholders Equity -204847.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009968 20240930 Stockholders Equity 527.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009968 20240930 Stockholders Equity -5217373.0000 USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20240930 Stockholders Equity -228191.0000 USD 0 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20230930 Stock Issued During Period Shares Common Shares Issued For Financing Expenses 125000.0000 shares 4 0001641172-25-009968 Equity Components= Common Stock;
0001641172-25-009968 20230930 Stock Issued During Period Shares Issued For Services 6667.0000 shares 4 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Shares Issued For Services One 3593.0000 shares 4 0001641172-25-009968 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Shares Issued For Services One 15201.0000 shares 4 0001641172-25-009968 Equity Components= Common Stock;
0001641172-25-009968 20230930 Stock Issued During Period Shares Other 11279.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009968 20230930 Stock Issued During Period Shares P Preferred Shares Issued For Interest 35012.0000 shares 4 0001641172-25-009968 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Shares Preferred Shares Issued For Accrued Salaries 15000.0000 shares 4 0001641172-25-009968 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Common Shares Issued For Financing Expenses USD 4 0001641172-25-009968 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Issued For Services 299999.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009968 20230930 Stock Issued During Period Value Issued For Services One 48372.0000 USD 4 0001641172-25-009968 Equity Components= Additional Paid In Capital;
0001641172-25-009968 20230930 Stock Issued During Period Value Issued For Services One USD 4 0001641172-25-009968 Equity Components= Common Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value New Issues 563722.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Stock Issued During Period Value New Issues USD 4 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Other USD 4 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value P Preferred Shares Issued For Interest USD 4 0001641172-25-009968 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Preferred Shares Issued For Accrued Salaries USD 4 0001641172-25-009968 Equity Components= Common Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Preferred Shares Issued For Debt 7.0000 USD 4 0001641172-25-009968 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Preferred Shares Issued For Services 13044.0000 USD 4 0001641172-25-009968
0001641172-25-009968 20230930 Stock Issued During Period Value Reverse Stock Splits USD 4 0001641172-25-009968 Class Of Stock= Preferred Stock Series N C; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Reverse Stock Splits USD 4 0001641172-25-009968 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Reverse Stock Splits 2.0000 USD 4 0001641172-25-009968 Equity Components= Common Stock;
0001641172-25-009968 20230930 Weighted Average Number Of Diluted Shares Outstanding 3536963.0000 shares 4 us-gaap/2024
0001641172-25-009968 20230930 Weighted Average Number Of Shares Outstanding Basic 3536963.0000 shares 4 us-gaap/2024
0001641172-25-009968 20240930 Liabilities Noncurrent USD 0 us-gaap/2024
0001641172-25-009968 20230930 Accounts Payable Current 1269041.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-009968 20240930 Accumulated Other Comprehensive Income Loss Net Of Tax -204847.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Accumulated Other Comprehensive Income Loss Net Of Tax USD 0 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Additional Paid In Capital 14684216.0000 USD 0 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Assets Current 143351.0000 USD 0 us-gaap/2024 Restatement= Restatement;
0001641172-25-009968 20230930 Common Stock Value 352.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Common Stock Value USD 0 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Common Stock Value 527.0000 USD 0 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest -873102.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Deferred Revenue Current 1465171.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party; Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Deferred Revenue Current USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-009968 20230930 Derivative Gain Loss On Derivative Net 2151755.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Derivative Gain Loss On Derivative Net -4091.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Derivative Gain Loss On Derivative Net 2726.0000 USD 4 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Fair Value Adjustment Of Warrants 4090.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Gains Losses On Extinguishment Of Debt USD 4 us-gaap/2024
0001641172-25-009968 20240930 General And Administrative Expense USD 4 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 General And Administrative Expense 58920.0000 USD 4 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Increase Decrease In Accounts Receivable 94874.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Liabilities 5371640.0000 USD 0 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Liabilities Noncurrent USD 0 us-gaap/2024 Restatement= Scenario Previously Reported;
0001641172-25-009968 20240930 Long Term Notes Payable USD 0 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Net Income Loss -668255.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Net Income Loss Available To Common Stockholders Basic -668255.0000 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Notes Payable Current 710.0000 USD 0 us-gaap/2024 Debt Instrument= David Koos; Related Party Transaction= Related Party;
0001641172-25-009968 20240930 Notes Payable Current 50000.0000 USD 0 us-gaap/2024 Debt Instrument= April Six Two Thousand Sixteen;
0001641172-25-009968 20240930 Notes Payable Current 1708.0000 USD 0 us-gaap/2024 Debt Instrument= David Koos; Related Party Transaction= Related Party;
0001641172-25-009968 20240930 Notes Payable Current 40000.0000 USD 0 us-gaap/2024 Debt Instrument= Zander Therapeutics Inc; Related Party Transaction= Related Party;
0001641172-25-009968 20230930 Operating Expenses 923509.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Operating Expenses -966.0000 USD 4 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Operating Income Loss -417221.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Other Assets USD 0 us-gaap/2024 Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-009968 20220930 Preferred Stock Shares Authorized 540000000.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-009968 20240930 Preferred Stock Shares Authorized 800000000.0000 shares 0 us-gaap/2024
0001641172-25-009968 20240930 Preferred Stock Shares Issued 10123771.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-009968 20230930 Preferred Stock Value 40.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock;
0001641172-25-009968 20240930 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Preferred Stock; Restatement= Restatement Adjustment;
0001641172-25-009968 20240930 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Restatement= Restatement Adjustment;
0001641172-25-009968 20230930 Prepaid Expense Current 10000.0000 USD 0 us-gaap/2024
0001641172-25-009968 20240930 Professional Fees 363961.0000 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Research And Development Expense 212297.0000 USD 4 us-gaap/2024
0001641172-25-009968 20230930 Shares Outstanding 15007.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Shares Outstanding 15007.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Shares Outstanding 5258235.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009968 20220930 Stockholders Equity USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009968 20230930 Stockholders Equity 2.0000 USD 0 us-gaap/2024 Class Of Stock= Preferred Stock Series N C; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stockholders Equity 3.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stockholders Equity 2.0000 USD 0 us-gaap/2024 Class Of Stock= Preferred Stock Series N C; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Shares Issued Preferred Shares For Dividend 9694152.0000 shares 4 0001641172-25-009968 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Common Shares Issued For Financing Expenses USD 4 0001641172-25-009968 Class Of Stock= Preferred Stock Series N C; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Common Shares Issued For Financing Expenses USD 4 0001641172-25-009968 Equity Components= Retained Earnings;
0001641172-25-009968 20240930 Stock Issued During Period Value Common Shares Issued For Financing Expenses 145500.0000 USD 4 0001641172-25-009968
0001641172-25-009968 20240930 Stock Issued During Period Value Common Shares Issued For Financing Expenses 145450.0000 USD 4 0001641172-25-009968 Equity Components= Additional Paid In Capital;
0001641172-25-009968 20230930 Stock Issued During Period Value Issued For Services 300000.0000 USD 4 us-gaap/2024
0001641172-25-009968 20240930 Stock Issued During Period Value Issued For Services USD 4 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value New Issues 563622.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009968 20230930 Stock Issued During Period Value Other USD 4 us-gaap/2024 Class Of Stock= Preferred Stock Series N C; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Other USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009968 20230930 Stock Issued During Period Value P Preferred Shares Issued For Interest USD 4 0001641172-25-009968 Equity Components= Common Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Preferred Shares Issued For Accrued Salaries USD 4 0001641172-25-009968 Equity Components= Retained Earnings;
0001641172-25-009968 20230930 Stock Issued During Period Value Preferred Shares Issued For Debt 761500.0000 USD 4 0001641172-25-009968
0001641172-25-009968 20230930 Stock Issued During Period Value Preferred Shares Issued For Debt USD 4 0001641172-25-009968 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Stock Issued During Period Value Preferred Shares Issued For Services USD 4 0001641172-25-009968 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20230930 Stock Issued During Period Value Reverse Stock Splits USD 4 0001641172-25-009968 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-009968 20240930 Weighted Average Number Of Diluted Shares Outstanding 4110265.0000 shares 4 us-gaap/2024
0001641172-25-011206 20240930 Accumulated Other Comprehensive Income Loss Net Of Tax -204847.0000 USD 0 us-gaap/2024
0001641172-25-011206 20231231 Accumulated Other Comprehensive Income Unrealized Loss -204847.0000 USD 1 0001641172-25-011206
0001641172-25-011206 20241231 Amortization Of Debt Discount Premium 12639.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Cash And Cash Equivalents At Carrying Value 135.0000 USD 0 us-gaap/2024
0001641172-25-011206 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 124497.0000 USD 0 us-gaap/2024
0001641172-25-011206 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -581.0000 USD 1 us-gaap/2024
0001641172-25-011206 20240930 Common Stock Shares Issued 3750565.0000 shares 0 us-gaap/2024
0001641172-25-011206 20231231 Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest -349780.0000 USD 1 us-gaap/2024
0001641172-25-011206 20240930 Deferred Revenue Current 1465171.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-011206 20240930 Deferred Revenue Current USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-011206 20241231 Deferred Revenue Current USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-011206 20241231 Derivative Liabilities 1820106.0000 USD 0 us-gaap/2024
0001641172-25-011206 20231231 Earnings Per Share Diluted -0.0400 USD 1 us-gaap/2024
0001641172-25-011206 20231231 Financing Fees USD 1 0001641172-25-011206
0001641172-25-011206 20241231 Financing Fees USD 1 0001641172-25-011206
0001641172-25-011206 20231231 Gains Losses On Extinguishment Of Debt USD 1 us-gaap/2024
0001641172-25-011206 20241231 Gains Losses On Extinguishment Of Debt USD 1 us-gaap/2024
0001641172-25-011206 20231231 General And Administrative Expense 12419.0000 USD 1 us-gaap/2024
0001641172-25-011206 20231231 Increase Decrease In Accounts Payable 14509.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Increase Decrease In Common Stock Issued For Expenses USD 1 0001641172-25-011206
0001641172-25-011206 20241231 Increase Decrease In Derivative Liabilities 416016.0000 USD 1 us-gaap/2024
0001641172-25-011206 20231231 Interest Expense Nonoperating 17784.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Liabilities And Stockholders Equity 191416.0000 USD 0 us-gaap/2024
0001641172-25-011206 20240930 Liabilities Noncurrent USD 0 us-gaap/2024
0001641172-25-011206 20241231 Net Income Loss USD 1 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-011206 20231231 Net Loss -144913.0000 USD 1 0001641172-25-011206
0001641172-25-011206 20240930 Notes Payable Current 1708.0000 USD 0 us-gaap/2024 Debt Instrument= David Koos; Related Party Transaction= Related Party;
0001641172-25-011206 20240930 Notes Payable Current 100000.0000 USD 0 us-gaap/2024 Debt Instrument= March Eight Two Thousand Sixteen;
0001641172-25-011206 20240930 Notes Payable Current 40000.0000 USD 0 us-gaap/2024 Debt Instrument= Zander Therapeutics Inc; Related Party Transaction= Related Party;
0001641172-25-011206 20241231 Notes Payable Current 46599.0000 USD 0 us-gaap/2024 Debt Instrument= B S T Partners; Related Party Transaction= Related Party;
0001641172-25-011206 20241231 Operating Income Loss -61378.0000 USD 1 us-gaap/2024
0001641172-25-011206 20231231 Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax -204847.0000 USD 1 us-gaap/2024
0001641172-25-011206 20241231 Preferred Shares Issued For Debt USD 1 0001641172-25-011206
0001641172-25-011206 20240930 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Shares Authorized 600000.0000 shares 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-011206 20240930 Preferred Stock Shares Issued 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-011206 20241231 Preferred Stock Shares Outstanding 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-011206 20241231 Research And Development Expense USD 1 us-gaap/2024
0001641172-25-011206 20231231 Shares Outstanding 15007.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20240930 Shares Outstanding 10123771.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20240930 Shares Outstanding 15007.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20241231 Shares Outstanding 15007.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20230930 Stockholders Equity 3.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20241231 Stockholders Equity 15455134.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-011206 20241231 Stock Issued During Period Value Stock Dividend USD 1 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-011206 20181130 Unrealized Gain Loss On Investments -123733.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-011206 20241231 Weighted Average Number Of Diluted Shares Outstanding 4110265.0000 shares 1 us-gaap/2024
0001641172-25-012619 20250331 Amortization Of Financing Costs And Discounts 25278.0000 USD 2 us-gaap/2024
0001641172-25-012619 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -42924.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Common Stock Shares Issued 21554704.0000 shares 0 us-gaap/2024
0001641172-25-012619 20240331 Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest -472234.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Derivative Gain Loss On Derivative Net 128963.0000 USD 1 us-gaap/2024
0001641172-25-012619 20240930 Derivative Liabilities 1404090.0000 USD 0 us-gaap/2024
0001641172-25-012619 20240930 Derivative Liabilities 802337.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender One;
0001641172-25-012619 20250331 Derivative Liabilities 400000.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender Five;
0001641172-25-012619 20250331 Derivative Liabilities 252525.0000 USD 0 us-gaap/2024 Derivative Instrument Risk= Lender Six;
0001641172-25-012619 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -122454.0000 USD 1 us-gaap/2024
0001641172-25-012619 20240331 Income Tax Expense Benefit USD 2 us-gaap/2024
0001641172-25-012619 20250331 Increase Decrease In Accounts Receivable 54847.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Liabilities Current 5867880.0000 USD 0 us-gaap/2024
0001641172-25-012619 20240930 Marketable Securities Current 11238.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Related Party Transactions By Related Party= Zander Therapeutics Inc;
0001641172-25-012619 20240331 Net Cash Provided By Used In Financing Activities 328734.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Notes Payable Current 50000.0000 USD 0 us-gaap/2024 Debt Instrument= April Six Two Thousand Sixteen;
0001641172-25-012619 20250331 Notes Payable Current 87215.0000 USD 0 us-gaap/2024 Debt Instrument= B S T Partners; Related Party Transaction= Related Party;
0001641172-25-012619 20250331 Operating Expenses 292857.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Preferred Shares Issued For Interest USD 2 0001641172-25-012619
0001641172-25-012619 20250331 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001641172-25-012619 20240930 Preferred Stock Shares Authorized 20000.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock;
0001641172-25-012619 20240930 Preferred Stock Value 3.0000 USD 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock;
0001641172-25-012619 20250331 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Preferred Stock;
0001641172-25-012619 20250331 Preferred Stock Value USD 0 us-gaap/2024 Class Of Stock= Series A A Preferred Stock;
0001641172-25-012619 20240331 Profit Loss -267386.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Profit Loss -534739.0000 USD 2 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-012619 20240331 Research And Development Expense 87661.0000 USD 2 us-gaap/2024
0001641172-25-012619 20250331 Research And Development Expense USD 1 us-gaap/2024
0001641172-25-012619 20240930 Retained Earnings Accumulated Deficit -20417118.0000 USD 0 us-gaap/2024
0001641172-25-012619 20240331 Revenue From Contract With Customer Excluding Assessed Tax 59064.0000 USD 1 us-gaap/2024
0001641172-25-012619 20230930 Shares Outstanding 15007.0000 shares 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240930 Shares Outstanding 29338.0000 shares 0 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240331 Stockholders Equity 40.0000 USD 0 us-gaap/2024 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240331 Stockholders Equity -20016249.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-012619 20240930 Stockholders Equity 2.0000 USD 0 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240930 Stockholders Equity 15403050.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-012619 20240930 Stockholders Equity 527.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-012619 20250331 Stock Issued During Period Shares Stock Splits 15426385.0000 shares 2 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-012619 20250331 Stock Issued During Period Value Issued For Services USD 2 us-gaap/2024 Class Of Stock= Series M Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20250331 Stock Issued During Period Value Issued For Services USD 2 us-gaap/2024 Class Of Stock= Series N C Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20240331 Stock Issued During Period Value New Issues USD 2 us-gaap/2024 Class Of Stock= Series A A Preferred Stock; Equity Components= Preferred Stock;
0001641172-25-012619 20250331 Stock Issued During Period Value Stock Dividend -1543.0000 USD 2 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-012619 20240930 Accounts Receivable Net Current 94873.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-012619 20250331 Accounts Receivable Net Current 149723.0000 USD 0 us-gaap/2024
0001641172-25-012619 20250331 Amortization Of Debt Discount Premium 12639.0000 USD 1 us-gaap/2024

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Increase Decrease In Accounts Receivable us-gaap/2024 0 0 monetary D C Increase (Decrease) in Accounts Receivable The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary D C Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.
Rental Expense 0001641172-25-012619 1 0 monetary D D Rent Rental expense.
Amortization Of Debt Discount Premium us-gaap/2024 0 0 monetary D D Amortization of Debt Discount (Premium) Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
Assets Current us-gaap/2024 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 0 0 monetary D C Revenue from Contract with Customer, Excluding Assessed Tax Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Stock Issued During Period Value Reverse Stock Splits 0001641172-25-009968 1 0 monetary D C March 6,2023 reverse stock split Stock issued during period value reverse stock splits.
Deferred Revenue Current us-gaap/2024 0 0 monetary I C Deferred Revenue, Current Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.
Stock Issued During Period Value Issued For Services One 0001641172-25-009968 1 0 monetary D C Preferred Shares Issued for Nonemployee Services Stock issued during period value issued for services one.
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 0 0 monetary D C Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Liabilities us-gaap/2024 0 0 monetary I C Liabilities Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
Liabilities And Stockholders Equity us-gaap/2024 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Proceeds From Repayments Of Secured Debt us-gaap/2024 0 0 monetary D D Proceeds from (Repayments of) Secured Debt Amount of cash inflow (outflow) from long-term debt wholly or partially secured by collateral. Excludes tax exempt secured debt.
Professional Fees us-gaap/2024 0 0 monetary D D Professional Fees A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.
Retained Earnings Accumulated Deficit us-gaap/2024 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Stock Issued During Period Shares Issued For Services us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Issued for Services Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
Stock Issued During Period Shares Common Shares Issued For Financing Expenses 0001641172-25-009968 1 0 shares D Common shares issued for financing expenses, shares Stock issued during period shares common shares issued for financing expenses.
Stock Issued During Period Shares Issued Preferred Shares For Services 0001641172-25-009968 1 0 shares D Preferred Shares Issued for Services, shares
Accounts Receivable Net Current us-gaap/2024 0 0 monetary I D Accounts Receivable, after Allowance for Credit Loss, Current Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Common Shares Issued For Interest 0001641172-25-011206 1 0 monetary D C Common shares Issued for Interest Common shares issued for interest.
Additional Paid In Capital us-gaap/2024 0 0 monetary I C Additional Paid in Capital Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
Common Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Common Stock, Par or Stated Value Per Share Face amount or stated value per share of common stock.
Common Stock Shares Outstanding us-gaap/2024 0 0 shares I Common Stock, Shares, Outstanding Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Preferred Shares Issued For Interest 0001641172-25-011206 1 0 monetary D C Preferred Shares issued for Interest Preferred shares issued for interest.
Income Tax Expense Benefit us-gaap/2024 0 0 monetary D D Income Tax Expense (Benefit) Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Long Term Notes Payable us-gaap/2024 0 0 monetary I C Notes Payable, Noncurrent Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
Net Income Loss us-gaap/2024 0 0 monetary D C Net Income (Loss) Attributable to Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Prepaid Expense Current us-gaap/2024 0 0 monetary I D Prepaid Expense, Current Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
Stockholders Equity us-gaap/2024 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Diluted The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Preferred Shares Distributed As Dividend 0001641172-25-009968 1 0 monetary D C PreferredSharesDistributedAsDividend
Preferred Shares Issued For Interest 0001641172-25-009968 1 0 monetary D C Preferred Shares issued for Interest Preferred shares issued for interest.
Stock Issued During Period Shares Issued For Services One 0001641172-25-009968 1 0 shares D March 6,2023 reverse stock split, shares Stock issued during period shares issued for services one.
Stock Issued During Period Value Common Shares Issued For Financing Expenses 0001641172-25-009968 1 0 monetary D C Common Shares issued for Financing Expenses Stock issued during period value common shares issued for financing expenses.
Accumulated Other Comprehensive Income Unrealized Loss 0001641172-25-012619 1 0 monetary D C Unrealized Loss Accumulated other comprehensive income unrealized loss.
Preferred Shares Issued For Interest 0001641172-25-012619 1 0 monetary D C Preferred Shares issued for Interest Preferred shares issued for interest.
Assets us-gaap/2024 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 0 0 monetary I C Accumulated Other Comprehensive Income (Loss), Net of Tax Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.
Cash us-gaap/2024 0 0 monetary I D Cash Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
Common Stock Shares Issued us-gaap/2024 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Accrued Liabilities Current us-gaap/2024 0 0 monetary I C Accrued Liabilities, Current Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Earnings Per Share Diluted us-gaap/2024 0 0 perShare D Earnings Per Share, Diluted The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Increase Decrease In Prepaid Expense us-gaap/2024 0 0 monetary D C Increase (Decrease) in Prepaid Expense The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax us-gaap/2024 0 0 monetary D C OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.
Proceeds From Notes Payable us-gaap/2024 0 0 monetary D D Proceeds from Notes Payable The cash inflow from a borrowing supported by a written promise to pay an obligation.
Derivative Liabilities us-gaap/2024 0 0 monetary I C Derivative Liability Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
Interest Expense Nonoperating us-gaap/2024 0 0 monetary D D Interest Expense, Nonoperating Amount of interest expense classified as nonoperating.
Liabilities Current us-gaap/2024 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Marketable Securities Current us-gaap/2024 0 0 monetary I D Marketable Securities, Current Amount of investment in marketable security, classified as current.
Preferred Stock Shares Issued us-gaap/2024 0 0 shares I Preferred Stock, Shares Issued Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.
Share Based Compensation us-gaap/2024 0 0 monetary D D Share-Based Payment Arrangement, Noncash Expense Amount of noncash expense for share-based payment arrangement.
Stock Issued During Period Value Issued For Services us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Issued for Services Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
Unrealized Gain Loss On Investments us-gaap/2024 0 0 monetary D C Unrealized Gain (Loss) on Investments Amount of unrealized gain (loss) on investment.
Accumulated Other Comprehensive Income Unrealized Loss 0001641172-25-009968 1 0 monetary D C Unrealized Loss
Financing Fees 0001641172-25-009968 1 0 monetary D D FinancingFees Financing fees.
Stock Issued During Period Preferred Shares Issued For Services 0001641172-25-009968 1 0 shares D Preferred Shares Issued for Nonemployee Services, shares Preferred shares issued for nonemployee services.
Stock Issued During Period Shares Preferred Shares Issued For Debt 0001641172-25-009968 1 0 shares D Preferred Shares Issued for Debt, shares Stock issued during period shares preferred shares issued for debt.
Stock Issued During Period Value Preferred Shares Issued For Debt 0001641172-25-009968 1 0 monetary D C Preferred Shares Issued for Debt Stock issued during period value preferred shares issued for debt.
Cash Paid For Interest 0001641172-25-011206 1 0 monetary D C Cash Paid for Interest Cash paid for interest.
Net Loss 0001641172-25-011206 1 0 monetary D C Net Income (loss)
Liabilities Noncurrent us-gaap/2024 0 0 monetary I C Liabilities, Noncurrent Amount of obligation due after one year or beyond the normal operating cycle, if longer.
Accumulated Other Comprehensive Income Unrealized Loss 0001641172-25-011206 1 0 monetary D C Unrealized Loss Accumulated other comprehensive income unrealized loss.
Common Shares Issued For Debt 0001641172-25-012619 1 0 monetary D C Common shares Issued for Debt Common shares issued for debt
Preferred Shares Issued For Debt 0001641172-25-012619 1 0 monetary D C Preferred Shares Issued for Debt Preferred shares issued for debt.
Amortization Of Financing Costs And Discounts us-gaap/2024 0 0 monetary D D Amortization of Debt Issuance Costs and Discounts Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.
Cash And Cash Equivalents At Carrying Value us-gaap/2024 0 0 monetary I D Cash and Cash Equivalents, at Carrying Value Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Other Liabilities Current us-gaap/2024 0 0 monetary I C Other Liabilities, Current Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
Other Noncash Income Expense us-gaap/2024 0 0 monetary D C Other Noncash Income (Expense) Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.
Preferred Stock Value us-gaap/2024 0 0 monetary I C Preferred Stock, Value, Issued Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
Proceeds From Repayments Of Notes Payable us-gaap/2024 0 0 monetary D D Proceeds from (Repayments of) Notes Payable Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.
Profit Loss us-gaap/2024 0 0 monetary D C Net Income (Loss), Including Portion Attributable to Noncontrolling Interest The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
Common Shares Issued For Interest 0001641172-25-009968 1 0 monetary D C Common shares Issued for Interest Common shares issued for interest.
Common Stock Issued For Compensation 0001641172-25-009968 1 0 monetary D D Common Stock issued for Compensation Common stock issued for compensation.
Stock Issued During Period Value Preferred Shares Issued For Dividend 0001641172-25-009968 1 0 monetary D C Preferred Shares Distributed as dividend
Convertible Note Payable Current 0001641172-25-012619 1 0 monetary I C Convertible notes payable, related parties, net of unamortized debt discount Convertible note payable current.
Net Cash Provided By Used In Operating Activities us-gaap/2024 0 0 monetary D Net Cash Provided by (Used in) Operating Activities Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Notes Payable Current us-gaap/2024 0 0 monetary I C Notes Payable, Current Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
Operating Expenses us-gaap/2024 0 0 monetary D D Operating Expenses Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
Operating Income Loss us-gaap/2024 0 0 monetary D C Operating Income (Loss) The net result for the period of deducting operating expenses from operating revenues.
Stock Issued During Period Shares Other us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Other Number of shares of stock issued attributable to transactions classified as other.
Stock Issued During Period Shares P Preferred Shares Issued For Interest 0001641172-25-009968 1 0 shares D Preferred Shares Issued for Interest, shares Stock issued during period shares p preferred shares issued for interest.
Stock Issued During Period Shares Preferred Shares Issued For Accrued Salaries 0001641172-25-009968 1 0 shares D Preferred Shares issued for accrued salaries, shares Stock issued during period shares preferred shares issued for accrued salaries.
General And Administrative Expense us-gaap/2024 0 0 monetary D D General and Administrative Expense The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Cash Paid For Interest 0001641172-25-012619 1 0 monetary D C Cash Paid for Interest Cash paid for interest.
Common Stock Value us-gaap/2024 0 0 monetary I C Common Stock, Value, Issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
Research And Development Expense us-gaap/2024 0 0 monetary D D Research and Development Expense Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
Stock Issued During Period Shares New Issues us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, New Issues Number of new stock issued during the period.
Stock Issued During Period Shares Stock Splits us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Stock Splits Number of shares issued during the period as a result of a stock split.
Common Shares Issued For Interest 0001641172-25-012619 1 0 monetary D C Common shares Issued for Interest Common shares issued for interest.
Increase Decrease In Accounts Payable us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accounts Payable The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
Accounts Payable Current us-gaap/2024 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Common Stock Shares Authorized us-gaap/2024 0 0 shares I Common Stock, Shares Authorized The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Gains Losses On Extinguishment Of Debt us-gaap/2024 0 0 monetary D C Gain (Loss) on Extinguishment of Debt Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
Fair Value Adjustment Of Warrants us-gaap/2024 0 0 monetary D D Fair Value Adjustment of Warrants Amount of expense (income) related to adjustment to fair value of warrant liability.
Net Cash Provided By Used In Financing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Financing Activities Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Net Income Loss Available To Common Stockholders Basic us-gaap/2024 0 0 monetary D C Net Income (Loss) Available to Common Stockholders, Basic Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
Preferred Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Preferred Stock, Par or Stated Value Per Share Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
Shares Outstanding us-gaap/2024 0 0 shares I Shares, Outstanding Number of shares issued which are neither cancelled nor held in the treasury.
Stock Issued During Period Value Stock Dividend us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Stock Dividend Value of stock issued to shareholders as a dividend during the period.
Stock Issued During Period Shares Issued Preferred Shares For Dividend 0001641172-25-009968 1 0 shares D Preferred Shares Distributed as dividend, shares
Stock Issued During Period Value Preferred Shares Issued For Services 0001641172-25-009968 1 0 monetary D C Preferred Shares Issued for Services
Earnings Per Share Basic us-gaap/2024 0 0 perShare D Earnings Per Share, Basic The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Increase Decrease In Unearned Premiums us-gaap/2024 0 0 monetary D D Increase (Decrease) in Unearned Premiums Amount of increase (decrease) unearned premiums written. Excludes portion of unearned premiums amortized into income.
Preferred Stock Shares Authorized us-gaap/2024 0 0 shares I Preferred Stock, Shares Authorized The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
Preferred Stock Shares Outstanding us-gaap/2024 0 0 shares I Preferred Stock, Shares Outstanding Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
Proceeds From Issuance Of Common Stock us-gaap/2024 0 0 monetary D D Proceeds from Issuance of Common Stock The cash inflow from the additional capital contribution to the entity.
Stock Issued During Period Value New Issues us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, New Issues Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
Preferred Shares Issued For Debt 0001641172-25-009968 1 0 monetary D C Preferred Shares issued for Debt Preferred shares issued for debt.
Stock Issued During Period Value P Preferred Shares Issued For Interest 0001641172-25-009968 1 0 monetary D C Preferred Shares Issued for Interest Stock issued during period value p preferred shares issued for interest.
Stock Issued During Period Value Preferred Shares Issued For Accrued Salaries 0001641172-25-009968 1 0 monetary D C Preferred Shares issued for accrued salaries Stock issued during period value preferred shares issued for accrued salaries.
Common Stock Issued For Compensation 0001641172-25-011206 1 0 monetary D D Common Stock issued for Compensation Common stock issued for compensation.
Convertible Note Payable Current 0001641172-25-011206 1 0 monetary I C Convertible notes payable, related parties, net of unamortized debt discount Convertible note payable current.
Financing Fees 0001641172-25-011206 1 0 monetary D D FinancingFees Financing fees.
Preferred Shares Issued For Debt 0001641172-25-011206 1 0 monetary D C Preferred Shares Issued for Debt Preferred shares issued for debt.
Rental Expense 0001641172-25-011206 1 0 monetary D D Rent Rental expense.
Derivative Gain Loss On Derivative Net us-gaap/2024 0 0 monetary D C Derivative, Gain (Loss) on Derivative, Net Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.
Increase Decrease In Accrued Liabilities us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accrued Liabilities The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
Increase Decrease In Derivative Liabilities us-gaap/2024 0 0 monetary D D Increase (Decrease) in Derivative Liabilities The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).
Other Assets us-gaap/2024 0 0 monetary I D Other Assets Amount of assets classified as other.
Stock Issued During Period Value Other us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Other Value of shares of stock issued attributable to transactions classified as other.
Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Basic Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Convertible Note Payable Current 0001641172-25-009968 1 0 monetary I C Convertible notes payable, related parties, net of unamortized debt discount Convertible note payable current.
Increase Decrease In Common Stock Issued For Expenses 0001641172-25-009968 1 0 monetary D D Common Stock issued for Expenses Increase decrease in common stock issued for expenses.
Rental Expense 0001641172-25-009968 1 0 monetary D D Rent Rental expense.
Increase Decrease In Common Stock Issued For Expenses 0001641172-25-011206 1 0 monetary D D Common Stock issued for Expenses Increase decrease in common stock issued for expenses.

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0001641172-25-011206 2 15 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash 0
0001641172-25-009968 2 16 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash 0
0001641172-25-009968 2 17 BS 0 H Accounts Receivable Net Current us-gaap/2024 Accounts receivable, related party 0
0001641172-25-009968 2 18 BS 0 H Prepaid Expense Current us-gaap/2024 Prepaid expenses 0
0001641172-25-009968 2 19 BS 0 H Assets Current us-gaap/2024 Total Current Assets 0
0001641172-25-009968 2 21 BS 0 H Marketable Securities Current us-gaap/2024 Investment securities, related party 0
0001641172-25-009968 2 22 BS 0 H Other Assets us-gaap/2024 Total Other Assets 0
0001641172-25-009968 2 23 BS 0 H Assets us-gaap/2024 TOTAL ASSETS 0
0001641172-25-009968 2 26 BS 0 H Accounts Payable Current us-gaap/2024 Accounts payable 0
0001641172-25-009968 2 27 BS 0 H Accrued Liabilities Current us-gaap/2024 Accrued expenses 0
0001641172-25-009968 2 28 BS 0 H Notes Payable Current us-gaap/2024 Notes payable 0
0001641172-25-009968 2 29 BS 0 H Deferred Revenue Current us-gaap/2024 Unearned Income 0
0001641172-25-009968 2 30 BS 0 H Derivative Liabilities us-gaap/2024 Derivative liability 0
0001641172-25-009968 2 31 BS 0 H Convertible Note Payable Current 0001641172-25-009968 Convertible notes payable, related parties, net of unamortized debt discount 0
0001641172-25-009968 2 32 BS 0 H Other Liabilities Current us-gaap/2024 Other current liabilities 0
0001641172-25-009968 2 33 BS 0 H Liabilities Current us-gaap/2024 Total Current Liabilities 0
0001641172-25-009968 2 35 BS 0 H Long Term Notes Payable us-gaap/2024 Notes Payable 0
0001641172-25-009968 2 36 BS 0 H Liabilities Noncurrent us-gaap/2024 Total Long Term Liabilities 0
0001641172-25-009968 2 37 BS 0 H Liabilities us-gaap/2024 TOTAL LIABILITIES 0
0001641172-25-009968 2 39 BS 0 H Common Stock Value us-gaap/2024 Common Stock ($.0001 par value) 5,800,000,000 authorized and 5,258,235 and 3,506,366 shares issued and outstanding, respectively 0
0001641172-25-009968 2 40 BS 0 H Preferred Stock Value us-gaap/2024 Preferred Stock, Value 0
0001641172-25-009968 2 41 BS 0 H Additional Paid In Capital us-gaap/2024 Additional Paid in capital 0
0001641172-25-009968 2 42 BS 0 H Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Other Comprehensive Income 0
0001641172-25-009968 2 43 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Retained Earnings (Deficit) 0
0001641172-25-009968 2 44 BS 0 H Stockholders Equity us-gaap/2024 Total Stockholders Equity (Deficit) 0
0001641172-25-009968 2 45 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 TOTAL LIABILITIES & STOCKHOLDERS EQUITY (DEFICIT) 0
0001641172-25-009968 3 9 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Common stock, par value 0
0001641172-25-009968 3 10 BS 1 H Common Stock Shares Authorized us-gaap/2024 Common stock, shares authorized 0
0001641172-25-009968 3 11 BS 1 H Common Stock Shares Issued us-gaap/2024 Common stock, shares issued 0
0001641172-25-009968 3 12 BS 1 H Common Stock Shares Outstanding us-gaap/2024 Common stock, shares outstanding 0
0001641172-25-009968 3 13 BS 1 H Preferred Stock Par Or Stated Value Per Share us-gaap/2024 Preferred stock, par value 0
0001641172-25-009968 3 14 BS 1 H Preferred Stock Shares Authorized us-gaap/2024 Preferred stock, shares authorized 0
0001641172-25-009968 3 15 BS 1 H Preferred Stock Shares Issued us-gaap/2024 Preferred stock, shares issued 0
0001641172-25-009968 3 16 BS 1 H Preferred Stock Shares Outstanding us-gaap/2024 Preferred stock, shares outstanding 0
0001641172-25-009968 4 7 IS 0 H Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 Net revenue 0
0001641172-25-009968 4 9 IS 0 H Research And Development Expense us-gaap/2024 Research and Development 0
0001641172-25-009968 4 10 IS 0 H General And Administrative Expense us-gaap/2024 General and Administrative 0
0001641172-25-009968 4 11 IS 0 H Professional Fees us-gaap/2024 Consulting and Professional Fees 0
0001641172-25-009968 4 12 IS 0 H Rental Expense 0001641172-25-009968 Rent 0
0001641172-25-009968 4 13 IS 0 H Operating Expenses us-gaap/2024 Total operating expenses 0
0001641172-25-009968 4 14 IS 0 H Operating Income Loss us-gaap/2024 Loss from operations 0
0001641172-25-009968 4 16 IS 0 H Interest Expense Nonoperating us-gaap/2024 Interest Expense 1
0001641172-25-009968 4 17 IS 0 H Amortization Of Debt Discount Premium us-gaap/2024 Interest Expense attributable to Amortization of Discount 1
0001641172-25-009968 4 18 IS 0 H Derivative Gain Loss On Derivative Net us-gaap/2024 Derivative Income (Expense) 0
0001641172-25-009968 4 19 IS 0 H Financing Fees 0001641172-25-009968 Financing Fees 1
0001641172-25-009968 4 20 IS 0 H Gains Losses On Extinguishment Of Debt us-gaap/2024 Gain (Loss) on Extinguishment Convertible Debt 0
0001641172-25-009968 4 21 IS 0 H Other Noncash Income Expense us-gaap/2024 Total other income (expense), net 0
0001641172-25-009968 4 22 IS 0 H Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 Net loss before income taxes 0
0001641172-25-009968 4 23 IS 0 H Income Tax Expense Benefit us-gaap/2024 Income tax provision 0
0001641172-25-009968 4 24 IS 0 H Net Income Loss us-gaap/2024 Net loss 0
0001641172-25-009968 4 25 IS 0 H Net Income Loss Available To Common Stockholders Basic us-gaap/2024 Net income (loss) attributable to common shareholders 0
0001641172-25-009968 4 26 IS 0 H Earnings Per Share Basic us-gaap/2024 Net loss per common share attributable to Regen Biopharma shareholders, basic 0
0001641172-25-009968 4 27 IS 0 H Earnings Per Share Diluted us-gaap/2024 Net loss per common share attributable to Regen Biopharma shareholders, diluted 0
0001641172-25-009968 4 28 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 Number of weighted average shares - basic 0
0001641172-25-009968 4 29 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 Number of weighted average shares - diluted 0
0001641172-25-009968 6 1 CI 0 H Net Income Loss us-gaap/2024 Net Income ( Loss) 0
0001641172-25-009968 6 3 CI 0 H Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax us-gaap/2024 Unrealized Loss Investment Securities 0
0001641172-25-009968 6 4 CI 0 H Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Comprehensive Loss 0
0001641172-25-009968 7 17 EQ 0 H Stockholders Equity us-gaap/2024 Beginning balance, value 0
0001641172-25-009968 7 18 EQ 0 H Shares Outstanding us-gaap/2024 Balance, shares 0
0001641172-25-009968 7 19 EQ 0 H Stock Issued During Period Value Issued For Services us-gaap/2024 Common Shares issued for services 0
0001641172-25-009968 7 20 EQ 0 H Stock Issued During Period Shares Issued For Services us-gaap/2024 Common Shares issued for services, shares 0
0001641172-25-009968 7 21 EQ 0 H Stock Issued During Period Value Preferred Shares Issued For Debt 0001641172-25-009968 Preferred Shares Issued for Debt 0
0001641172-25-009968 7 22 EQ 0 H Stock Issued During Period Shares Preferred Shares Issued For Debt 0001641172-25-009968 Preferred Shares Issued for Debt, shares 0
0001641172-25-009968 7 23 EQ 0 H Stock Issued During Period Value P Preferred Shares Issued For Interest 0001641172-25-009968 Preferred Shares Issued for Interest 0
0001641172-25-009968 7 24 EQ 0 H Stock Issued During Period Shares P Preferred Shares Issued For Interest 0001641172-25-009968 Preferred Shares Issued for Interest, shares 0
0001641172-25-009968 7 25 EQ 0 H Stock Issued During Period Value Other us-gaap/2024 Common Shares Issued For Interest 0
0001641172-25-009968 7 26 EQ 0 H Stock Issued During Period Shares Other us-gaap/2024 Common Shares Issued For Interest, shares 0
0001641172-25-009968 7 27 EQ 0 H Stock Issued During Period Value Issued For Services One 0001641172-25-009968 Preferred Shares Issued for Nonemployee Services 0
0001641172-25-009968 7 28 EQ 0 H Stock Issued During Period Preferred Shares Issued For Services 0001641172-25-009968 Preferred Shares Issued for Nonemployee Services, shares 0
0001641172-25-009968 7 29 EQ 0 H Stock Issued During Period Value Reverse Stock Splits 0001641172-25-009968 March 6,2023 reverse stock split 0
0001641172-25-009968 7 30 EQ 0 H Stock Issued During Period Shares Issued For Services One 0001641172-25-009968 March 6,2023 reverse stock split, shares 0
0001641172-25-009968 7 31 EQ 0 H Stock Issued During Period Value Preferred Shares Issued For Accrued Salaries 0001641172-25-009968 Preferred Shares issued for accrued salaries 0
0001641172-25-009968 7 32 EQ 0 H Stock Issued During Period Shares Preferred Shares Issued For Accrued Salaries 0001641172-25-009968 Preferred Shares issued for accrued salaries, shares 0
0001641172-25-009968 7 33 EQ 0 H Stock Issued During Period Value Common Shares Issued For Financing Expenses 0001641172-25-009968 Common Shares issued for Financing Expenses 0
0001641172-25-009968 7 34 EQ 0 H Stock Issued During Period Shares Common Shares Issued For Financing Expenses 0001641172-25-009968 Common shares issued for financing expenses, shares 0
0001641172-25-009968 7 35 EQ 0 H Net Income Loss us-gaap/2024 Net Income ( Loss) for the year 0
0001641172-25-009968 7 36 EQ 0 H Stock Issued During Period Value New Issues us-gaap/2024 Common Shares issued for Cash 0
0001641172-25-009968 7 37 EQ 0 H Stock Issued During Period Shares New Issues us-gaap/2024 Common Shares issued for Cash, shares 0
0001641172-25-009968 7 38 EQ 0 H Stock Issued During Period Value Preferred Shares Issued For Services 0001641172-25-009968 Preferred Shares Issued for Services 0
0001641172-25-009968 7 39 EQ 0 H Stock Issued During Period Shares Issued Preferred Shares For Services 0001641172-25-009968 Preferred Shares Issued for Services, shares 0
0001641172-25-009968 7 40 EQ 0 H Stock Issued During Period Value Preferred Shares Issued For Dividend 0001641172-25-009968 Preferred Shares Distributed as dividend 0
0001641172-25-009968 7 41 EQ 0 H Stock Issued During Period Shares Issued Preferred Shares For Dividend 0001641172-25-009968 Preferred Shares Distributed as dividend, shares 0
0001641172-25-009968 7 42 EQ 0 H Accumulated Other Comprehensive Income Unrealized Loss 0001641172-25-009968 Unrealized Loss 0
0001641172-25-009968 7 43 EQ 0 H Stockholders Equity us-gaap/2024 Balance September 30, 2024 (As Restated) 0
0001641172-25-009968 7 44 EQ 0 H Shares Outstanding us-gaap/2024 Balance, shares 0
0001641172-25-009968 9 2 CF 0 H Net Income Loss us-gaap/2024 Net Income (loss) 0
0001641172-25-009968 9 3 CF 0 H Increase Decrease In Common Stock Issued For Expenses 0001641172-25-009968 Common Stock issued for Expenses 0
0001641172-25-009968 9 4 CF 0 H Share Based Compensation us-gaap/2024 Preferred Stock issued as compensation 0
0001641172-25-009968 9 5 CF 0 H Common Stock Issued For Compensation 0001641172-25-009968 Common Stock issued for Compensation 0
0001641172-25-009968 9 6 CF 0 H Amortization Of Financing Costs And Discounts us-gaap/2024 Interest expense attributable to amortization of Discount 0
0001641172-25-009968 9 7 CF 0 H Fair Value Adjustment Of Warrants us-gaap/2024 Derivative Expense 0
0001641172-25-009968 9 8 CF 0 H Gains Losses On Extinguishment Of Debt us-gaap/2024 (Gain) Loss on forgiveness of Debt 1
0001641172-25-009968 9 9 CF 0 H Increase Decrease In Accounts Payable us-gaap/2024 Accounts Payable 0
0001641172-25-009968 9 10 CF 0 H Increase Decrease In Accounts Receivable us-gaap/2024 Accounts Receivable 1
0001641172-25-009968 9 11 CF 0 H Increase Decrease In Accrued Liabilities us-gaap/2024 Accrued Expenses 0
0001641172-25-009968 9 12 CF 0 H Increase Decrease In Prepaid Expense us-gaap/2024 Prepaid Expenses 1
0001641172-25-009968 9 13 CF 0 H Increase Decrease In Unearned Premiums us-gaap/2024 Unearned Income 0
0001641172-25-009968 9 14 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net Cash Provided by (Used in) Operating Activities 0
0001641172-25-009968 9 15 CF 0 H Proceeds From Repayments Of Secured Debt us-gaap/2024 Repayments on convertible notes payable 0
0001641172-25-009968 9 16 CF 0 H Proceeds From Notes Payable us-gaap/2024 Borrowings from notes payable 0
0001641172-25-009968 9 17 CF 0 H Proceeds From Issuance Of Common Stock us-gaap/2024 Proceeds from issuances of common stock 0
0001641172-25-009968 9 18 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net Cash Provided by (Used in) Financing Activities 0
0001641172-25-009968 9 19 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 Net Increase (Decrease) in Cash 0
0001641172-25-009968 9 20 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 Cash at Beginning of Period 0
0001641172-25-009968 9 21 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 Cash at End of Period 0
0001641172-25-009968 9 23 CF 0 H Preferred Shares Issued For Debt 0001641172-25-009968 Preferred Shares issued for Debt 0
0001641172-25-009968 9 24 CF 0 H Common Shares Issued For Interest 0001641172-25-009968 Common shares Issued for Interest 0
0001641172-25-009968 9 25 CF 0 H Preferred Shares Issued For Interest 0001641172-25-009968 Preferred Shares issued for Interest 0
0001641172-25-009968 9 26 CF 0 H Preferred Shares Distributed As Dividend 0001641172-25-009968 Preferred Shares Distributed as dividend 0
0001641172-25-011206 2 16 BS 0 H Accounts Receivable Net Current us-gaap/2024 Accounts receivable, related party 0
0001641172-25-011206 2 17 BS 0 H Prepaid Expense Current us-gaap/2024 Prepaid expenses 0
0001641172-25-011206 2 18 BS 0 H Assets Current us-gaap/2024 Total Current Assets 0
0001641172-25-011206 2 19 BS 0 H Marketable Securities Current us-gaap/2024 Investment securities, related party 0
0001641172-25-011206 2 20 BS 0 H Other Assets us-gaap/2024 Total Other Assets 0
0001641172-25-011206 2 21 BS 0 H Assets us-gaap/2024 TOTAL ASSETS 0
0001641172-25-011206 2 23 BS 0 H Accounts Payable Current us-gaap/2024 Accounts payable 0
0001641172-25-011206 2 24 BS 0 H Accrued Liabilities Current us-gaap/2024 Accrued expenses 0
0001641172-25-011206 2 25 BS 0 H Notes Payable Current us-gaap/2024 Notes payable 0
0001641172-25-011206 2 26 BS 0 H Deferred Revenue Current us-gaap/2024 Unearned income 0
0001641172-25-011206 2 27 BS 0 H Derivative Liabilities us-gaap/2024 Derivative liability 0
0001641172-25-011206 2 28 BS 0 H Convertible Note Payable Current 0001641172-25-011206 Convertible notes payable, related parties, net of unamortized debt discount 0
0001641172-25-011206 2 29 BS 0 H Other Liabilities Current us-gaap/2024 Other current liabilities 0
0001641172-25-011206 2 30 BS 0 H Liabilities Current us-gaap/2024 Total Current Liabilities 0
0001641172-25-011206 2 31 BS 0 H Long Term Notes Payable us-gaap/2024 Notes Payable 0
0001641172-25-011206 2 32 BS 0 H Liabilities Noncurrent us-gaap/2024 Total Long Term Liabilities 0
0001641172-25-011206 2 33 BS 0 H Liabilities us-gaap/2024 TOTAL LIABILITIES 0
0001641172-25-011206 9 3 CF 0 H Share Based Compensation us-gaap/2024 Preferred Stock issued as compensation 0
0001641172-25-011206 2 34 BS 0 H Common Stock Value us-gaap/2024 Common Stock ($.0001 par value) 5,800,000,000 authorized and 21,554,704 and 3,750,565 shares issued and outstanding, respectively 0
0001641172-25-011206 2 35 BS 0 H Preferred Stock Value us-gaap/2024 Preferred Stock, Value 0
0001641172-25-011206 2 36 BS 0 H Additional Paid In Capital us-gaap/2024 Additional Paid in capital 0
0001641172-25-011206 2 37 BS 0 H Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Other Comprehensive Income 0
0001641172-25-011206 2 38 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Retained Earnings (Deficit) 0
0001641172-25-011206 2 39 BS 0 H Stockholders Equity us-gaap/2024 Total Stockholders Equity (Deficit) 0
0001641172-25-011206 2 40 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 TOTAL LIABILITIES & STOCKHOLDERS EQUITY (DEFICIT) 0
0001641172-25-011206 3 9 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Common stock, par value 0
0001641172-25-011206 3 10 BS 1 H Common Stock Shares Authorized us-gaap/2024 Common stock, shares authorized 0
0001641172-25-011206 3 11 BS 1 H Common Stock Shares Issued us-gaap/2024 Common stock, shares issued 0
0001641172-25-011206 3 12 BS 1 H Common Stock Shares Outstanding us-gaap/2024 Common stock, shares outstanding 0
0001641172-25-011206 3 13 BS 1 H Preferred Stock Par Or Stated Value Per Share us-gaap/2024 Preferred stock, par value 0
0001641172-25-011206 3 14 BS 1 H Preferred Stock Shares Authorized us-gaap/2024 Preferred stock, shares authorized 0
0001641172-25-011206 3 15 BS 1 H Preferred Stock Shares Issued us-gaap/2024 Preferred stock, shares issued 0
0001641172-25-011206 3 16 BS 1 H Preferred Stock Shares Outstanding us-gaap/2024 Preferred stock, shares outstanding 0
0001641172-25-011206 4 7 IS 0 H Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 Net revenue 0
0001641172-25-011206 4 8 IS 0 H Research And Development Expense us-gaap/2024 Research and Development 0
0001641172-25-011206 4 9 IS 0 H General And Administrative Expense us-gaap/2024 General and Administrative 0
0001641172-25-011206 4 10 IS 0 H Professional Fees us-gaap/2024 Consulting and Professional Fees 0
0001641172-25-011206 4 11 IS 0 H Rental Expense 0001641172-25-011206 Rent 0
0001641172-25-011206 4 12 IS 0 H Operating Expenses us-gaap/2024 Total operating expenses 0
0001641172-25-011206 4 13 IS 0 H Operating Income Loss us-gaap/2024 Loss from operations 0
0001641172-25-011206 4 14 IS 0 H Interest Expense Nonoperating us-gaap/2024 Interest Expense 1
0001641172-25-011206 4 15 IS 0 H Amortization Of Debt Discount Premium us-gaap/2024 Interest Expense attributable to Amortization of Discount 1
0001641172-25-011206 4 16 IS 0 H Unrealized Gain Loss On Investments us-gaap/2024 Unrealized Gain ( Loss) on sale of Investment Securities 0
0001641172-25-011206 4 17 IS 0 H Derivative Gain Loss On Derivative Net us-gaap/2024 Derivative Income (Expense) 0
0001641172-25-011206 4 18 IS 0 H Financing Fees 0001641172-25-011206 Financing Fees 1
0001641172-25-011206 4 19 IS 0 H Gains Losses On Extinguishment Of Debt us-gaap/2024 Gain (Loss) on Extinguishment Convertible Debt 0
0001641172-25-011206 4 20 IS 0 H Other Noncash Income Expense us-gaap/2024 Total other income (expense), net 0
0001641172-25-011206 4 21 IS 0 H Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 Net loss before income taxes 0
0001641172-25-011206 4 22 IS 0 H Income Tax Expense Benefit us-gaap/2024 Income tax provision 0
0001641172-25-011206 4 23 IS 0 H Net Loss 0001641172-25-011206 Net loss 0
0001641172-25-011206 4 24 IS 0 H Net Income Loss Available To Common Stockholders Basic us-gaap/2024 Net income (loss) attributable to common shareholders 0
0001641172-25-011206 4 25 IS 0 H Earnings Per Share Basic us-gaap/2024 Net loss per common share attributable to Regen Biopharma shareholders, basic 0
0001641172-25-011206 4 26 IS 0 H Earnings Per Share Diluted us-gaap/2024 Net loss per common share attributable to Regen Biopharma shareholders, diluted 0
0001641172-25-011206 4 27 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 Number of weighted average shares - basic 0
0001641172-25-011206 4 28 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 Number of weighted average shares - diluted 0
0001641172-25-011206 6 1 CI 0 H Net Income Loss us-gaap/2024 Net Income ( Loss) 0
0001641172-25-011206 6 3 CI 0 H Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax us-gaap/2024 Unrealized Loss Investment Securities 0
0001641172-25-011206 6 4 CI 0 H Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Comprehensive Loss 0
0001641172-25-011206 7 16 EQ 0 H Stockholders Equity us-gaap/2024 Balance 0
0001641172-25-011206 7 17 EQ 0 H Shares Outstanding us-gaap/2024 Balance, shares 0
0001641172-25-011206 7 18 EQ 0 H Stock Issued During Period Value New Issues us-gaap/2024 Common Shares issued for Cash 0
0001641172-25-011206 7 19 EQ 0 H Stock Issued During Period Shares New Issues us-gaap/2024 Common Shares issued for Cash, shares 0
0001641172-25-011206 7 20 EQ 0 H Accumulated Other Comprehensive Income Unrealized Loss 0001641172-25-011206 Unrealized Loss 0
0001641172-25-011206 7 21 EQ 0 H Net Income Loss us-gaap/2024 Net Income (Loss) 0
0001641172-25-011206 7 22 EQ 0 H Stock Issued During Period Value Stock Dividend us-gaap/2024 Common stock paid as dividend 0
0001641172-25-011206 7 23 EQ 0 H Stock Issued During Period Shares Stock Splits us-gaap/2024 Common stock paid as dividend, shares 0
0001641172-25-011206 7 24 EQ 0 H Stock Issued During Period Value Other us-gaap/2024 Common stock issued in satisfaction of debt 0
0001641172-25-011206 7 25 EQ 0 H Stock Issued During Period Shares Other us-gaap/2024 Common stock issued in satisfaction of debt, shares 0
0001641172-25-011206 7 26 EQ 0 H Stock Issued During Period Value Issued For Services us-gaap/2024 Common stock issued for Services 0
0001641172-25-011206 7 27 EQ 0 H Stock Issued During Period Shares Issued For Services us-gaap/2024 Common stock issued for Services, shares 0
0001641172-25-011206 7 28 EQ 0 H Stockholders Equity us-gaap/2024 Balance 0
0001641172-25-011206 7 29 EQ 0 H Shares Outstanding us-gaap/2024 Balance, shares 0
0001641172-25-011206 9 2 CF 0 H Net Loss 0001641172-25-011206 Net Income (loss) 0
0001641172-25-011206 9 4 CF 0 H Common Stock Issued For Compensation 0001641172-25-011206 Common Stock issued for Compensation 0
0001641172-25-011206 9 5 CF 0 H Amortization Of Financing Costs And Discounts us-gaap/2024 Increase (Decrease) in Interest expense attributable to amortization of Discount 0
0001641172-25-011206 9 6 CF 0 H Increase Decrease In Common Stock Issued For Expenses 0001641172-25-011206 Common Stock issued for Expenses 0
0001641172-25-011206 9 7 CF 0 H Increase Decrease In Accounts Payable us-gaap/2024 Increase (Decrease) in Accounts Payable 0
0001641172-25-011206 9 8 CF 0 H Increase Decrease In Accounts Receivable us-gaap/2024 (Increase) Decrease in Accounts Receivable 1
0001641172-25-011206 9 9 CF 0 H Increase Decrease In Accrued Liabilities us-gaap/2024 Increase (Decrease) in accrued Expenses 0
0001641172-25-011206 9 10 CF 0 H Increase Decrease In Prepaid Expense us-gaap/2024 (Increase) Decrease in Prepaid Expenses 1
0001641172-25-011206 9 11 CF 0 H Increase Decrease In Derivative Liabilities us-gaap/2024 Increase ( Decrease) in Derivative Expense 0
0001641172-25-011206 9 12 CF 0 H Increase Decrease In Unearned Premiums us-gaap/2024 Increase ( Decrease) in Unearned Income 0
0001641172-25-011206 9 13 CF 0 H Gains Losses On Extinguishment Of Debt us-gaap/2024 (Gain)Loss on forgiveness of Debt 1
0001641172-25-011206 9 14 CF 0 H Unrealized Gain Loss On Investments us-gaap/2024 Unrealized Loss(Gain) on Investment Securities 1
0001641172-25-011206 9 15 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net Cash Provided by (Used in) Operating Activities 0
0001641172-25-011206 9 17 CF 0 H Proceeds From Repayments Of Secured Debt us-gaap/2024 Increase (Decrease)in Convertible Notes Payable 0
0001641172-25-011206 9 18 CF 0 H Proceeds From Notes Payable us-gaap/2024 Increase (Decrease)in Notes Payable 0
0001641172-25-011206 9 19 CF 0 H Proceeds From Issuance Of Common Stock us-gaap/2024 Increase ( Decrease) in Common Stock issued for cash 0
0001641172-25-011206 9 20 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net Cash Provided by (Used in) Financing Activities 0
0001641172-25-011206 9 21 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 Net Increase (Decrease) in Cash 0
0001641172-25-011206 9 22 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 Cash at Beginning of Period 0
0001641172-25-011206 9 23 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 Cash at End of Period 0
0001641172-25-011206 9 25 CF 0 H Preferred Shares Issued For Debt 0001641172-25-011206 Preferred Shares Issued for Debt 0
0001641172-25-011206 9 26 CF 0 H Cash Paid For Interest 0001641172-25-011206 Cash Paid for Interest 0
0001641172-25-011206 9 27 CF 0 H Common Shares Issued For Interest 0001641172-25-011206 Common shares Issued for Interest 0
0001641172-25-011206 9 28 CF 0 H Preferred Shares Issued For Interest 0001641172-25-011206 Preferred Shares issued for Interest 0
0001641172-25-012619 2 15 BS 0 H Cash us-gaap/2024 Cash 0
0001641172-25-012619 2 16 BS 0 H Accounts Receivable Net Current us-gaap/2024 Accounts receivable, related party 0
0001641172-25-012619 2 17 BS 0 H Prepaid Expense Current us-gaap/2024 Prepaid expenses 0
0001641172-25-012619 2 18 BS 0 H Assets Current us-gaap/2024 Total Current Assets 0
0001641172-25-012619 2 19 BS 0 H Marketable Securities Current us-gaap/2024 Investment securities, related party 0
0001641172-25-012619 2 20 BS 0 H Other Assets us-gaap/2024 Total Other Assets 0
0001641172-25-012619 2 21 BS 0 H Assets us-gaap/2024 TOTAL ASSETS 0
0001641172-25-012619 2 23 BS 0 H Accounts Payable Current us-gaap/2024 Accounts payable 0
0001641172-25-012619 2 24 BS 0 H Accrued Liabilities Current us-gaap/2024 Accrued expenses 0
0001641172-25-012619 2 25 BS 0 H Notes Payable Current us-gaap/2024 Notes payable 0
0001641172-25-012619 2 26 BS 0 H Deferred Revenue Current us-gaap/2024 Unearned income 0
0001641172-25-012619 2 27 BS 0 H Derivative Liabilities us-gaap/2024 Derivative liability 0
0001641172-25-012619 2 28 BS 0 H Convertible Note Payable Current 0001641172-25-012619 Convertible notes payable, related parties, net of unamortized debt discount 0
0001641172-25-012619 2 29 BS 0 H Other Liabilities Current us-gaap/2024 Other current liabilities 0
0001641172-25-012619 2 30 BS 0 H Liabilities Current us-gaap/2024 Total Current Liabilities 0
0001641172-25-012619 2 31 BS 0 H Long Term Notes Payable us-gaap/2024 Notes Payable 0
0001641172-25-012619 2 32 BS 0 H Liabilities Noncurrent us-gaap/2024 Total Long Term Liabilities 0
0001641172-25-012619 2 33 BS 0 H Liabilities us-gaap/2024 TOTAL LIABILITIES 0
0001641172-25-012619 2 34 BS 0 H Common Stock Value us-gaap/2024 Common Stock ($.0001 par value) 5,800,000,000 authorized and 21,554,704 and 5,258,235 shares issued and outstanding, respectively 0
0001641172-25-012619 2 35 BS 0 H Preferred Stock Value us-gaap/2024 Preferred Stock, Value 0
0001641172-25-012619 2 36 BS 0 H Additional Paid In Capital us-gaap/2024 Additional Paid in capital 0
0001641172-25-012619 2 37 BS 0 H Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Other Comprehensive Income 0
0001641172-25-012619 2 38 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Retained Earnings (Deficit) 0
0001641172-25-012619 2 39 BS 0 H Stockholders Equity us-gaap/2024 Total Stockholders Equity (Deficit) 0
0001641172-25-012619 2 40 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 TOTAL LIABILITIES & STOCKHOLDERS EQUITY (DEFICIT) 0
0001641172-25-012619 3 9 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Common stock, par value 0
0001641172-25-012619 3 10 BS 1 H Common Stock Shares Authorized us-gaap/2024 Common stock, shares authorized 0
0001641172-25-012619 3 11 BS 1 H Common Stock Shares Issued us-gaap/2024 Common stock, shares issued 0
0001641172-25-012619 3 12 BS 1 H Common Stock Shares Outstanding us-gaap/2024 Common stock, shares outstanding 0
0001641172-25-012619 3 13 BS 1 H Preferred Stock Par Or Stated Value Per Share us-gaap/2024 Preferred stock, par value 0
0001641172-25-012619 3 14 BS 1 H Preferred Stock Shares Authorized us-gaap/2024 Preferred stock, shares authorized 0
0001641172-25-012619 3 15 BS 1 H Preferred Stock Shares Issued us-gaap/2024 Preferred stock, shares issued 0
0001641172-25-012619 3 16 BS 1 H Preferred Stock Shares Outstanding us-gaap/2024 Preferred stock, shares outstanding 0
0001641172-25-012619 4 7 IS 0 H Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 Net revenue 0
0001641172-25-012619 4 8 IS 0 H Research And Development Expense us-gaap/2024 Research and Development 0
0001641172-25-012619 4 9 IS 0 H General And Administrative Expense us-gaap/2024 General and Administrative 0
0001641172-25-012619 4 10 IS 0 H Professional Fees us-gaap/2024 Consulting and Professional Fees 0
0001641172-25-012619 4 11 IS 0 H Rental Expense 0001641172-25-012619 Rent 0
0001641172-25-012619 4 12 IS 0 H Operating Expenses us-gaap/2024 Total operating expenses 0
0001641172-25-012619 4 13 IS 0 H Operating Income Loss us-gaap/2024 Loss from operations 0
0001641172-25-012619 4 14 IS 0 H Interest Expense Nonoperating us-gaap/2024 Interest Expense 1
0001641172-25-012619 4 15 IS 0 H Amortization Of Debt Discount Premium us-gaap/2024 Interest Expense attributable to Amortization of Discount 1
0001641172-25-012619 4 16 IS 0 H Derivative Gain Loss On Derivative Net us-gaap/2024 Derivative Income (Expense) 0
0001641172-25-012619 4 17 IS 0 H Other Noncash Income Expense us-gaap/2024 Total other income (expense), net 0
0001641172-25-012619 4 18 IS 0 H Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 Net loss before income taxes 0
0001641172-25-012619 4 19 IS 0 H Income Tax Expense Benefit us-gaap/2024 Income tax provision 0
0001641172-25-012619 4 20 IS 0 H Net Income Loss us-gaap/2024 Net loss 0
0001641172-25-012619 4 21 IS 0 H Net Income Loss Available To Common Stockholders Basic us-gaap/2024 Net income (loss) attributable to common shareholders 0
0001641172-25-012619 4 22 IS 0 H Earnings Per Share Basic us-gaap/2024 Net loss per common share attributable to Regen Biopharma shareholders, basic 0
0001641172-25-012619 4 23 IS 0 H Earnings Per Share Diluted us-gaap/2024 Net loss per common share attributable to Regen Biopharma shareholders, diluted 0
0001641172-25-012619 4 24 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 Number of weighted average shares - basic 0
0001641172-25-012619 4 25 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 Number of weighted average shares - diluted 0
0001641172-25-012619 6 1 CI 0 H Net Income Loss us-gaap/2024 Net Income ( Loss) 0
0001641172-25-012619 6 3 CI 0 H Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax us-gaap/2024 Unrealized Loss Investment Securities 0
0001641172-25-012619 6 4 CI 0 H Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Comprehensive Loss 0
0001641172-25-012619 7 16 EQ 0 H Stockholders Equity us-gaap/2024 Balance 0
0001641172-25-012619 7 17 EQ 0 H Shares Outstanding us-gaap/2024 Balance, shares 0
0001641172-25-012619 7 18 EQ 0 H Stock Issued During Period Value New Issues us-gaap/2024 Common Shares issued for Cash 0
0001641172-25-012619 7 19 EQ 0 H Stock Issued During Period Shares New Issues us-gaap/2024 Common Shares issued for Cash, shares 0
0001641172-25-012619 7 20 EQ 0 H Accumulated Other Comprehensive Income Unrealized Loss 0001641172-25-012619 Unrealized Loss 0
0001641172-25-012619 7 21 EQ 0 H Profit Loss us-gaap/2024 Net Income ( Loss) 0
0001641172-25-012619 7 22 EQ 0 H Stock Issued During Period Value Stock Dividend us-gaap/2024 Common stock paid as dividend 0
0001641172-25-012619 7 23 EQ 0 H Stock Issued During Period Shares Stock Splits us-gaap/2024 Common stock paid as dividend, shares 0
0001641172-25-012619 7 24 EQ 0 H Stock Issued During Period Value Other us-gaap/2024 Common stock issued in satisfaction of debt 0
0001641172-25-012619 7 25 EQ 0 H Stock Issued During Period Shares Other us-gaap/2024 Common stock issued in satisfaction of debt, shares 0
0001641172-25-012619 7 26 EQ 0 H Stock Issued During Period Value Issued For Services us-gaap/2024 Common stock issued for Services 0
0001641172-25-012619 7 27 EQ 0 H Stock Issued During Period Shares Issued For Services us-gaap/2024 Common stock issued for Services, shares 0
0001641172-25-012619 7 28 EQ 0 H Stockholders Equity us-gaap/2024 Balance 0
0001641172-25-012619 7 29 EQ 0 H Shares Outstanding us-gaap/2024 Balance, shares 0
0001641172-25-012619 9 2 CF 0 H Net Income Loss us-gaap/2024 Net Income (loss) 0
0001641172-25-012619 9 3 CF 0 H Common Stock Issued For Compensation 0001641172-25-012619 Common Stock issued for Compensation 0
0001641172-25-012619 9 4 CF 0 H Amortization Of Financing Costs And Discounts us-gaap/2024 Increase (Decrease) in Interest expense attributable to amortization of Discount 0
0001641172-25-012619 9 5 CF 0 H Increase Decrease In Accounts Payable us-gaap/2024 Increase (Decrease) in Accounts Payable 0
0001641172-25-012619 9 6 CF 0 H Increase Decrease In Accounts Receivable us-gaap/2024 (Increase) Decrease in Accounts Receivable 1
0001641172-25-012619 9 7 CF 0 H Increase Decrease In Accrued Liabilities us-gaap/2024 Increase (Decrease) in Accrued Expenses 0
0001641172-25-012619 9 8 CF 0 H Increase Decrease In Prepaid Expense us-gaap/2024 (Increase) Decrease in Prepaid Expenses 1
0001641172-25-012619 9 9 CF 0 H Increase Decrease In Derivative Liabilities us-gaap/2024 Increase ( Decrease) in Derivative Expense 0
0001641172-25-012619 9 10 CF 0 H Increase Decrease In Unearned Premiums us-gaap/2024 Increase ( Decrease) in Unearned Income 0
0001641172-25-012619 9 11 CF 0 H Unrealized Gain Loss On Investments us-gaap/2024 Unrealized Loss(Gain) on Investment Securities 1
0001641172-25-012619 9 12 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net Cash Provided by (Used in) Operating Activities 0
0001641172-25-012619 9 14 CF 0 H Proceeds From Repayments Of Secured Debt us-gaap/2024 Increase (Decrease) in Convertible Notes Payable 0
0001641172-25-012619 9 15 CF 0 H Proceeds From Repayments Of Notes Payable us-gaap/2024 Increase (Decrease) in Notes Payable 0
0001641172-25-012619 9 16 CF 0 H Proceeds From Issuance Of Common Stock us-gaap/2024 Increase ( Decrease) in Common Stock issued for cash 0
0001641172-25-012619 9 17 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net Cash Provided by (Used in) Financing Activities 0
0001641172-25-012619 9 18 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 Net Increase (Decrease) in Cash 0
0001641172-25-012619 9 19 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 Cash at Beginning of Period 0
0001641172-25-012619 9 20 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 Cash at End of Period 0
0001641172-25-012619 9 22 CF 0 H Common Shares Issued For Debt 0001641172-25-012619 Common shares Issued for Debt 0
0001641172-25-012619 9 23 CF 0 H Preferred Shares Issued For Debt 0001641172-25-012619 Preferred Shares Issued for Debt 0
0001641172-25-012619 9 24 CF 0 H Cash Paid For Interest 0001641172-25-012619 Cash Paid for Interest 0
0001641172-25-012619 9 25 CF 0 H Common Shares Issued For Interest 0001641172-25-012619 Common shares Issued for Interest 0
0001641172-25-012619 9 26 CF 0 H Preferred Shares Issued For Interest 0001641172-25-012619 Preferred Shares issued for Interest 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.